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Abstract
Shane Philippi
INVESTIGATIONS OF NOVEL STRATEGIES TO TREAT BACTERIAL
INFECTION AND DEVELOPMENT OF NEW REACTION METHODOLOGY
2018-2019
Lark Perez
Master of Science in Pharmaceutical Sciences

Quorum Sensing (QS), a form of bacteria communication mediated through
chemical signaling, was investigated in the bacterial pathogen Psuedomonas aeruginosa.
QS has the ability to regulate when a bacterial pathogen is infective or benign. LasR is
the main regulator in this system and is also the receptor targeted for inhibition. A
Structure Activity Relationship was produced for the system along with the binding
pocket being explored.
A new reaction methodology was developed inspired by the Haloform reaction.
The reaction was optimized based on solvent, stoichiometry, and conditions. Changing
the initial electrophile and the reagent nucleophile created the scope of the reaction.
A series of molecules were prepared as Narrow Spectrum Antibiotics against
both Psuedomonas aeruginosa and Acinetobacter baumannii. A Structure Activity
Relationship was created for these molecules testing three key positions of the structure
with steric and electronic changes. Optimization of the molecule leads to a potentially
new lead compound in the series. Future directions for the molecule are discussed in
order to further expand the SAR while also increasing stability of the molecules, and
possibly reducing toxicity.
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Chapter 1A
Development of Agonist and Antagonist of LasR
Introduction to Qurom Sensing
Due to the array of medically relevant cellular processes that are under the control
of LuxR-type quorum sensing circuits, significant effort has been directed toward the
identification of antagonist and agonist molecules in several different bacterial
pathogens.1-3 These efforts have led to the identification of antagonists and agonists of
quorum sensing from natural sources,4 diversity-oriented compound libraries,5,6 and
focused library synthesis.7,8 The most broadly explored class of LuxR-type receptor
ligands are based on the structural features found in the native HSLs (e.g. 1, Figure 1).
The wealth of studies in this area, maintaining the homoserine lactone while changing the
functionality of the acyl-tail is facilitated by ready synthesis of the HSL compound
libraries. Together these investigations targeting the modulation of quorum sensing in
Gram-negative bacteria have yielded numerous promising results and insightful structure
activity relationships.9,10
The inhibition of quorum sensing with small molecules offers a unique strategy
for the treatment and prevention of a number of acute and chronic bacterial infections, a
fact that is of particular significance given the rapid and ongoing spread of antimicrobialresistant bacteria.2,11,12 Through the inhibition of quorum sensing, control over expression
of virulence factors and biofilm formation is achieved, rendering the bacteria benign
while not directly affecting viability. This anti-infective approach is conceptually distinct
from traditional approaches for the treatment of bacterial infection that typically utilize
bactericidal or bacteriostatic molecules, targeting critical cellular processes.
1

As

exemplified by the spread of bacterial resistance, these treatments provide a considerable
growth advantage to bacteria that can resist the drug. Contrasting this approach, the
inhibition of quorum sensing does not affect cellular viability, decreasing the growth
advantage of resistance.13 Rather, this approach targets cellular signaling, inhibiting the
expression of virulence factors necessary for successful infection, rendering the bacteria
benign until the hosts immune system can clear the pathogen.2,14-16
Major challenges that remain in the development of an anti-quorum sensing
strategy targeting the development of antagonists of LasR and other LuxR-type receptors
is ligand potency and the complications of hydrolytic liability in HSL-based
antagonists.17 Here we advance a strategy to overcome the limitation of inhibitor potency
through the exploration of a novel, non-natural triaryl series of LasR quorum sensing
ligands. Further, many of the analogs examined in this study are anticipated to overcome
the limitations of the HSL-based agonists and antagonists by removing the
physiologically labile homoserine lactone functionality.18
Recently a highly potent agonist of quorum-sensing in P. aeruginosa was
identified from a high-throughput screen (2, Figure 2).5 While the activation of virulence
factor expression in this bacterial pathogen is not therapeutically desirable our rationale
to obtain the desired inhibitory function for this potent agonist through analog synthesis
is based on precedent. Most notably, a large number of inhibitors have been discovered
by systematic modification of HSLs, molecules which serve as natural QS activators. The
agonist discovered (2) bears many structural and pharmacological properties that
potentially make it superior to HSLs as a lead compound for the development of an antivirulence therapy, including the absence of the metabolically labile homoserine lactone.
Additionally, the potency of this molecule for activation of LasR is comparable to the
2

potency of the natural signaling molecule; however, compounds of this structure type
have never been systematically analyzed for the effect of their structure-activity
relationships (SARs).5,19 Here we describe the first systematic evaluation of the structureactivity relationships of this novel class of LasR QS modulators. Our studies reveal
critical details of the activity profile of this new ligand class for LasR activity and using
computational modeling we provide insight into the molecular interactions with LasR
that contribute to agonist and antagonist activity.
Library Synthesis
Challenging our efforts toward the goal of identifying inhibitors of LasR based on
the structure of 2 is the number of synthetic steps required for its assembly (Figure 1).19
Previous studies had described an eight step synthesis of 2, however, to prepare a library
of molecules related to 2 ideally required a more efficient synthetic route. Identification
of an alternative scaffold to target for structure-activity relationship studies was informed
by examination of the recently published crystal structure of the QS receptor in P.
aeruginosa, LasR, in the presence of 2.20 Analysis of the binding pocket for the ligand
suggested that a subtle structural change in the orientation of the amide bond in 2 (Figure
1, highlighted in blue) may be tolerated. Indeed, examination of the scaffold resulting
from the inversion of the amide linker between the “B-ring” and “C-ring” (highlighted in
red, 3) more closely maps onto the orientation of this structure in the native LasR agonist,
3-oxo-C12HSL (1).

3

Figure 1. Top - the structures of the native agonist of the QS receptor, LasR, 3-oxoC12HSL and the triaryl scaffolds evaluated as LasR agonists and antagonists in this
study. Bottom; a description of the modular chemical synthesis pathways for library
assembly.

Based on these target scaffolds, we have successfully identified two efficient and
modular synthetic routes (Figure 1) to analogs containing the core scaffold as in 2
(Scaffold #1) analogs containing the core scaffold as in 3 (Scaffold #2). In our optimized
six step synthesis of 2 and analogs of this structure, bromination and benzyl protection of
salicylamide is followed by reduction of the amide and introduction of the “C-ring”
through amidation with 11. Final incorporation of the “A-ring” is achieved through
4

deprotection of the phenol and esterification with 8. This route is modular, enabling ready
diversification of the “A-ring” and “C-ring” of the ligand and proceeds in 35% yield
overall from salicylamide. The synthesis of 3 and related analogs involves initial
coupling of 4 and 2-nitro aniline (5). Deprotection of the phenol and bromination of the
more electron rich “B-ring” proceeds smoothly to provide 7 which can be directly
esterified with 8. Overall, this route allows rapid diversification of the “A-ring” and “Cring” of 3, proceeding in four steps with 52% overall yield from 4.
Library Design and SAR
Analysis of the crystal structure of LasR complexed to 220 suggests that the two
terminal aromatic rings (Figure 1, labeled “A” and “C”) play an important role by
interacting with LasR whereas the central ring appears to play primarily a scaffolding
role in ligand binding. Therefore, we have focused our initial efforts on identifying the
structure activity correlations of the pendant ring structures (“A-ring” and “C-ring”)
while maintaining the structure of the central ring (“B-ring”). Our strategy involved
initial broad investigation of structure-activity relationships in the more readily
synthesized ligand series (Scaffold #2, e.g. 3) before returning to investigate key analogs
prepared based on Scaffold #1. While the two scaffolds differ only in the orientation of
one amide bond, we have observed some notable differences in biological activity for
analogs prepared on the two different scaffolds.
Our initial investigations of the structure activity relationships involved
modulation of the structure of the “A-ring” in Scaffold #2. From this series of structural
analogs, we observe a consistent dependence of substitution in this ring structure on the
potency of the molecules (Table 1). We discovered that substitution in the ortho-position
of the arene (entries 1, 4, 7, 9, 10, and 13-14) is critical for agonist activity. Interestingly,
5

the activity of the analogs bearing ortho-substitution appears to be largely independent of
the nature of the substituent. Analogs with electon-withdrawing substituents (halogen,
nitro, trifluoromethyl) and electron-donating groups (methyl, methoxy) in the orthoposition all are agonists with EC50 values between 2.4 and 15.8 μM. By contrast to
substitution in the ortho-position of the “A-ring”, substitution in the meta- or paraposition of the “A-ring” (entries 2-3, 5-7 and 11-12) leads to the complete loss of activity.
In support of the significance of ortho-substitution, an analog was prepared containing
chlorine atoms at both of the ortho-positions of the “A-ring” (entry 16) fully retains the
activity of the mono-ortho-chloro LasR agonist 3. We additionally find that the carbonyl
of the ester is not significant for agonist activity as an analog removing this functionality,
linking the “A-ring” through an ether linker (28, entry 17) retains full agonist activity.

6

Table 1
Structure-activity relationships of “A-ring” analogs.

EC50 values are reported as the mean of triplicate analysis with the range defining the
standard deviation. The native LasR agonist (1) was used as a control with an
EC50=72.9±24.6nM. b Maximal percent activation of GFP at 50 μM with respect to 3oxo-C12 HSL (1) as a positive control for LasR agonism, set at 100% activation.
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Generally we find that analogs with substituents in the ortho-position are potent agonists
whereas the meta- or para-substituted analogs are universally not active. This may
suggest that the binding pocket in LasR for this portion of the molecule is not able to
accommodate substituents in either the meta- or para-position. Further, the comparable
activities of the analogs containing electronically and sterically diverse substituents in the
ortho-position suggests that this substitution does not have a direct role interacting with
the receptor (no specific hydrogen-bonding or electronic interactions with the receptor)
but rather may simply play an anchoring role for the overall positioning of the “A-ring”.
In support of this hypothesis, analog 26, containing an ortho-bromo substituent and a
para-fluoro substituent is active as a LasR agonist (entry 15), while the analog containing
the para-fluoro substituent alone is inactive (entry 8). Further supporting the significance
of maintaining an ortho-substituent on the “A-ring” is the lack of agonist activity found
in analog 29 (entry 18) that possesses an unsubstituted phenyl ring at this position.
The ligands that were inactive as agonists in this series were further evaluated as
antagonists and were found to have no antagonist activity. This observation suggests that
the presence of minimally one ortho substituent on the “A-ring” of ligands in this series
is required for ligand binding to LasR in the cell.
To further investigate the strict requirement for the presence of an orthosubstituent on the “A-ring” for LasR agonist activity we performed computational
binding studies using the Schrodinger Drug Discovery Suite. We were pleased to find
that the MMGBSA scores (measure of binding affinity) from this computational binding
8

analysis for the full series of compounds in Table 1 was strongly correlated to the
observed biological activity of the analogs with the ortho-substituted analogs showing the
strongest binding and the unsubstituted phenyl “A-ring” analog (29) predicted to be a
poor LasR ligand (Table 2).

Table 2
Calculated binding energies for “A-ring” analogs.

Average calculated binding energy of analogs 3, 15, 18, 20, 21, 24 and 25. b Average
calculated binding energy of analogs 13, 16 and 22. c Average calculated binding energy
of analogs 14, 17, 19 and 23. d MMGBSA is reported as the average binding energy with
the error representing standard deviation.

MMGBSA Binding
Energy (kcal/mol)
Ortho-Substituted Analogsa

–87.12±20.87d

Meta-Substituted Analogsb

–37.35±6.15d

Para-Substituted Analogsc

–18.86±27.79d

Unsubstituted Phenyl
Analog 29

–11.05

9

Building on this result we computationally investigated the relative contributions
for each of the amino acids within the LasR binding pocket that, in sum, contribute to the
overall MMGBSA score for the compound. We hypothesized that this analysis may
enable the identification of key residues in LasR that contribute to ligand binding
rationalizing that the meta- and para- substituted “A-ring” analogs would lack these
stabilizing interactions or would display destabilizing interactions. We identified several
individual amino acids that showed variations in their extracted contribution to the
computational binding energies (Figure 2).
Generally, amino acids residues proximal to the 2-nitro aniline “C-ring” of the
analog, not varied in this series of analogs, displayed similar binding energies to each of
the ligands, irrespective of the substitution pattern on the “A-ring”. For example, W60
and F101 (Figure 3, light blue) independently contribute stabilizing binding interactions
to all of the analogs evaluated (Figure 2).
Some variations in the extracted binding energies are noted in the amino acid
residues responsible for interactions with the amide linker between the “C-ring” and “Bring” of the analogs. Amino acid residues which are highly conserved among soluble
HSL-binding proteins, Y56 and D73 (Figure 3, yellow), display different patterns of
binding between the analogs dependent on the substitution of the “A-ring”. While Y56
shows strongly stabilizing interactions with all analogs, by virtue of a hydrogen bond to
the carbonyl oxygen of the linker amide, this stabilizing interaction appears to be slightly
weakened in the binding of the para-substituted ligands (Figure 2). In contrast, the
10

interactions between the ligand and D73 are calculated to be generally low in energy with
ortho- and meta-substituted analogs however becomes significantly destabilizing in
interactions with ligands bearing a para-substituent in the “A-ring”. Apparently,
substitution in the para-position of the distant “A-ring” is effectively propagated through
the ligand to disrupt the hydrogen bonding interactions between LasR and the linker
amide of the ligand.

Figure 2. Computational binding contributions of individual amino acids in LasR, with
the ligands in Table 1. Energies are described in kcal/mol.

Not surprisingly, a series of amino acids in the binding pocket proximal to the “Aring” were found to be most significantly influenced by the structural changes
investigated in this ligand series. While much of this large portion of the HSL binding
pocket in LasR is hydrophobic, key amino acids displaying significant differences in
binding to the structural variations in the “A-ring” include Y47, R61, D65, V76, G126
and A127 (Figure 3, magenta). Two primary trends are noted in the binding contribution
of amino acids in this region of LasR. Firstly, in stabilizing interactions the orthosubstituted analogs show greater stabilization then meta- or para-substituted analogs.
11

This trend is exemplified in the binding contributions of Y47, V76 and G126 (Figure 2).
Secondly, two residues show strong destabilizing interactions uniquely with the parasubstituted analogs, D65 and A127 (Figure 3). These residues are located on opposing
sides of the binding pocket possibly suggesting that a steric clash on one side of the
ligand binding pocket pushes the ligand toward the opposing side of the binding pocket
resulting in destabilizing interactions with these two spatially separated amino acids.
Lastly, it should be noted that not all amino acids showed a preference for the orthosubstituted analogs. One residue analyzed, R61 shows significant destabilizing
interactions with both ortho- and meta-substituted analogs that is alleviated in the parasubstituted series of compounds.

Figure 3. Key residues in LasR shown with 3 docked. W60 and F101 are shown in light
blue, Y56 and D73 are shown in yellow and Y47, R61, D65, V76, G126 and A127 are
shown in magenta. Inset: a schematic representation highlighting these amino acids in
proximity to three regions of the ligand.
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While most analogs that we have analyzed with changes in the structure of the
“A-ring” were found to be either agonists or to have no activity, analogs with structural
changes in the “C-ring” have both changes in potency and changes in function (agonism
vs. antagonism). We first assessed the impact of the position of the nitro-substituent on
the activity of the molecules (Table 3, entries 1-3), revealing the importance of an orthonitro substituent. We then prepared a series of analogs in which the ortho-nitro group on
the “C-ring” of the parent compound (3) was exchanged for functionality that had been
previously found to be a suitable bioisostere of an aromatic nitro group.21 While the 2pyridine was observed to have no agonist activity (entry 4) the di-fluoro bioisostere was
found to show enhanced activity as a LasR agonist (entry 5). Introducing additional
electron-withdrawing substituents onto the ring (entry 6) had minimal effect on activity
however, interestingly, the pyrimidine analog (entry 7) was found to be active as an
agonist. Combining the 2-nitro substitution with a ring nitrogen at the 4-position (entry 8)
also provided an agonist of comparable activity to the parent compound. Therefore,
within the series of aromatic and hetero-aromatic analogs of this ring highest agonist
activity was noted with the di-fluoro analog (entry 5) and the 2-pyridine and meta- and
para-nitro analogs were found to be inactive. Based on published crystal-structure
analysis from which the ortho-nitro ring serves the role of a mimic of the homoserine
lactone characteristic of this class of signaling molecules having direct interactions with a
conserved tryptophan (W60) in the LasR binding pocket. Accordingly, we replaced the 2nitro aniline “C-ring” with a homoserine lactone (37). Notably, this analog displays
significantly enhanced activity to 3 and the native LasR signaling agonist, 3-oxo-C12HSL, with an EC50 value of 0.9 nM (Entry 9).
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Table 3
Structure-activity relationships of “C-ring” analogs.

EC50 values are reported as the mean of triplicate analysis with the range defining the
standard deviation. The native LasR agonist (1) was used as a control with an
EC50=72.9±24.6nM. b Maximal percent activation of GFP at 50 μM with respect to 3oxo-C12 HSL (1) as a positive control for LasR agonism, set at 100% activation.
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We next turned our attention to an evaluation of selected analogs identified as
significant in our investigation of the SAR of Scaffold #2 as described in Tables 1 and 2.
Accordingly we prepared a series of analogs based on Scaffold #1, maintaining the orthochloro substitutent on the “A-ring” and incorporating three selected “C-ring” motifs. We
selected the new 2-pyridine, di-fluoro and pyrimidine “C-ring” analogs for this analysis
as these analogs displayed a range of agonist activities in our initial library. Therefore, we
evaluated analogs 32, 33, 35 and 38-40 for both their agonist and antagonist activity in
the LasR quorum sensing reporter strain (Figure 4). In our analysis, we found that 2pyridine analog 32, earlier observed to show no agonist activity against LasR (Table 3,
entry 4) possessed potent antagonist activity with an IC50 of 42μM. We additionally
prepared this analog with the amide linker between the “B-ring” and the “C-ring”
reversed and observed that this analog (38) had similarly high LasR antagonist activity
(Figure 4). We next prepared an analog containing a reversed amide corresponding to the
potent difluoro arene full LasR agonist 33 (Figure 4, EC50 = 46nM). To our surprise, the
analog containing the reversed amide as in Scaffold #1 (39) was not an agonist of LasR,
instead it displayed a change in function, instead acting as an partial antagonist of LasR
QS with an IC50 of 65uM (80% maximal inhibition). In contrast to this finding, when we
prepared the reversed amide analog of the weak agonist pyrimidine 34 (EC50 = 0.6μM)
we found the new analog (40) to similarly be a weak agonist of LasR with an EC50 of 1.6
μM. Therefore, while in most cases we evaluated changing the orientation of the amide
linker results in small (2-3 fold) changes in the potency of the analog, in certain cases
simply reversing this amide linkage appears to result in a shift from LasR agonism to
antagonism.

15

Figure 4. The effect of amide bond orientation on activity of selected LasR ligands.
Bioassay and data fitting was performed according to the standard procedure. EC50 and
IC50 values are reported as the mean of triplicate analysis with the range defining the
standard deviation.

We turned to computational modeling in an effort to further investigate these
observations. In contrast to the ligands in Table 1, where a clear binding preference was
noted for ortho- substituted “A-ring” analogs based on MMGBSA scores, in this analysis
the ligands shown in Figure 5 are universally predicted to have show comparable binding
to LasR. As before, we therefore evaluated the independent contributions of amino acid
residues within the LasR binding pocket (Figure 5). Importantly, all of the residues that
are proximal to the “A-ring” and “B-ring”, which are unchanged in this series of ligands
16

show minimal changes in their binding energies (e.g. Y47, R61, D65, V76, G126 and
A127, Figure 5). One significant change in binding energies at the individual amino acid
level is noted and occurs with a residue predicted to be close to the “C-ring” of the
ligand. The pyridine analog 32, an antagonist, shows a stronger binding interaction with
Y56 along with diminished binding to W60 when compared to 3 and 33, two agonists.
Evaluation of the docking poses for these ligands reveals a notable reorganization of the
ligand which likely leads to the above changes in the binding energies for Y56 and W60
(Figure 6). In these poses there is a clear shift in protein binding involving rotation of the
“C-ring” from interaction between the 2-nitro substituent of the agonist 3 with W60 (light
blue, Figure 6A) to an interaction between the 2-pyridine of the antagoinst 32 with Y56
(yellow, Figure 6B).

Figure 5. Computational binding contributions of individual amino acids in LasR, with
agonist ligands 3 (dark grey) and 33 (light grey) and the antagonist ligand 32 (medium
grey).

We hypothesized that this subtle change in protein binding may represent a novel
trigger to shift LasR from an agonized to an antagonized state. To test this hypothesis we
prepared an analog containing a 3-pyridine ring in leiu of the 2-pyridine ring contained in
17

the antagonist 32. Due to the placement of the ring nitrogen, the pyridine should be
prevented from interacting with Y56 and we hypothesized would therefore lose its
antagonist activity. We accordingly evaluated 41 (Figure 7) and found this analog to
show no antagonist activity, in striking contrast to the 2-pyridine antagonist (32), this
analog acts as an agonist of LasR.

Figure 6. Comparison of the docking poses for LasR agonist 3 (panel A) and LasR
antagonist 32 (panel B).

We had previously identified a novel series of potent maleimide containing LasR
antagoinsts that act to irreversibly inhibit LasR through covalent modification of Cys79
in the LasR binding pocket.22 Structurally, the maleimide functionality we identified as
being central to the LasR antagonist activity maps onto the “A-ring” of the current ligand
series. Accordingly we investigated a series of hybrid analogs containing a 2-pyridine or
a homoseriene lactone in the “C-ring” position and a pendant maleimide as the “A-ring”
structure (Figure 9). Upon analysis of this series of compounds we found that all fully
antagonized LasR, however with considerably different levels of activity (Figure 9).
Analog 42, combining the 2-pyridine “C-ring” with a pendant maleimide was found to be
a weak antagonist of LasR. It appears that combining the two structural features we had
identified to independently lead to LasR antagonism, through two distinct mechanisms of
18

interaction with LasR, do not work together in this ligand in an additive manner. Analogs
43 and 44 both containing a homoseriene lactone in place of the 2-nitro aniline “C-ring”
display a striking dependence of activity on the linker length to the maleimide. Consistent
with our previous studies for ligands containing this amide isomer22, the maleimide linker
containing two methylene units (44) was more potent with an IC50 of 23.8μM. This
analog represents one of the most potent antagonists of LasR discovered, being
comparable in activity to the most potent analogs we had previously identified.22

Figure 7. The 3-pyridine analog is a LasR agonist. Bioassay and data fitting was
performed according to the standard procedure. EC50 and IC50 values are reported as the
mean of triplicate analysis with the range defining the standard deviation.

Figure 8. Hybrid analogs combining optimized structural features identified, which in
this study with a maleimide for LasR irreversible inhibition. Bioassay and data fitting was
performed according to the standard procedure. EC50 and IC50 values are reported as the
mean of triplicate analysis with the range defining the standard deviation.
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Conclusions
We have evaluated a series of synthetic libraries of non-natural modulators of
LasR-mediated QS in P. aeruginosa. The compounds prepared are significant as they
represent a novel drug-like scaffold for the preparation of inhibitors of bacterial
virulence. We have identified several notable stricture-activity relationships and in so
doing have paved the way for the rational design of potent drug-like inhibitors of LasR
QS. Using a combination of experimental and computational investigations, our studies
have unveiled a new potential strategy for inducing LasR antagonism and have defined
critical structural features of this novel ligand class for receptor binding.
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Chapter 1B
Experimental Data for LasR Discussion
General Experimental
Unless otherwise noted, all reactions were performed in flame-dried glassware
under an atmosphere of nitrogen or argon using dried reagents and solvents. All
chemicals were purchased from commercial vendors and used without further
purification. Anhydrous clean solvents were purchased from commercial vendors.
Flash chromatography was performed using standard grade silica gel 60 230-400
mesh from SORBENT Technologies or was performed using a Biotage Flash Purification
system equipped with Biotage SNAP columns. All purifications were performed using
gradients of mixtures of ethyl acetate and hexanes. Analytical thin-layer chromatography
was carried out using Silica G TLC plates, 200 μm with UV254 fluorescent indicator
(SORBENT Technologies), and visualization was performed by staining and/or by
absorbance of UV light.
NMR spectra were recorded using a Varian Mercury Plus spectrometer (400 MHz
for 1H-NMR; 100 MHz for

13

C-NMR). Chemical shifts are reported in parts per million

(ppm) and were calibrated according to residual protonated solvent. Mass spectroscopy
data was collected using an Agilent 1100-Series LC/MSD Trap LC-MS or a Micromass
Quattromicro with a Waters 2795 Separations Module LC-MS with acetonitrile
containing 0.1% formic acid as the mobile phase in positive ionization mode. Purity was
determined on a Agilent 1100 series equipped with a Phenomenex Kinetex 2.6 µm C18UPLC column using a gradient of water to acetonitrile with 0.1% TFA.
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All final compounds were evaluated to be of greater then 90% purity by analysis
of 1H-NMR, 13C-NMR, and analytical HPLC. Full 1H-NMR and 13C-NMR spectra are
included below.
2-(Benzyloxy)-3,5-dibromobenzamide, 10.
Salicylamide (10.0 g, 72.9 mmol) was dissolved in glacial acetic acid (146 mL, 0.5 M)
and Br2 (11.2 mL, 218.7 mmol) was added dropwise. The reaction stirred overnight at
room temperature and then was quenched with water (500 mL). Product was filtered and
washed with a small amount of water and then dried in a dessicator, affording 20.2 g of
the desired product, which was used crude in the subsequent step, 93.5% yield. 3,5Dibromo-2-hydroxybenzamide (10.0 g, 33.7 mmol) was dissolved in acetone (337 mL,
0.1 M) and K2CO3 (5.58 g, 40.4 mmol) was added, followed by benzyl bromide (4.80
mL, 40.4 mmol) dropwise. The mixture was stirred at reflux overnight and then was
cooled to room temperature. Potassium carbonate was filtered off (filtrate was washed
with more acetone) and the solvent was removed in vacuo. The product was
recrystallized in acetone, affording 11.3 g of the desired product, 87.1% yield. Spectral
data was consistent with previous report.22
N-(2-(Benzyloxy)-3,5-dibromobenzyl)-2-nitrobenzamide, 12.
2-(Benzyloxy)-3,5-dibromobenzamide (1.0 g, 2.58 mmol) was dissolved in BH3.THF
(13.24 mL, 13.24 mmol) under N2 and the mixture was heated to reflux. The reaction
stirred for 48 h at 75 °C and was monitored by TLC (10 mL additional BH 3.THF was
added at 30 h). Methanol (10 mL x 2) was added dropwise to quench the reaction, and
then the solvent was removed in vacuo. The product was used crude in the subsequent
step without purification. 1H NMR (400 MHz, DMSO-d6) δ 7.95 (d, J = 2.5 Hz, 1H), 7.91
(s, 1H), 7.74 (s, 1H), 7.60 (d, J = 2.4 Hz, 1H), 7.48 – 7.42 (m, 2H), 7.40 – 7.29 (m, 3H),
22

4.95 (s, 2H), 4.36 (t, 2H).

13

C NMR (101 MHz, DMSO-d6) δ 151.79, 136.32, 136.20,

134.68, 131.19, 128.40, 128.39, 119.03, 116.67, 60.79, 29.25. 2-Nitrobenzonic acid
(534.8 mg, 3.20 mmol) was dissolved in CH2Cl2 and the solution was cooled to 0 °C
under N2. Oxalyl chloride (0.550 mL, 6.40 mmol) was added dropwise, followed by
DMF (1 drop). The reaction was allowed to warm to room temperature as it stirred for 2
h. Solvent and excess oxalyl chloride was removed in vacuo and then the residue was
resuspended in CH2Cl2. This acid chloride was added dropwise to a solution of (2(benzyloxy)-3,5-dibromophenyl)methanamine (655 mg, 1.60 mmol) in CH2Cl2 (32 mL,
0.1 M). Triethylamine (1.56 mL, 11.2 mmol) was added, followed by DMAP (cat.) and
the mixture stirred overnight at room temperature. After quenching the reaction with
water (25 mL), more CH2Cl2 was added (50 mL) and the organic layer was washed with
HCl (50 mL, 1 M), sat. NaHCO3 (50 mL) and then brine (50 mL), and then was dried
over Na2SO4. Purification via silica-gel column chromatography (product elutes around
30% EtOAc) afforded 354 mg of the desired product, 42.5% yield. 1H NMR (400 MHz,
CDCl3) δ 8.04 (dd, 1H), 7.69 (d, J = 2.4 Hz, 1H), 7.66 – 7.59 (m, 1H), 7.59 – 7.53 (m,
2H), 7.44 – 7.40 (m, 2H), 7.37 – 7.29 (m, 3H), 7.26 – 7.20 (m, 1H), 5.81 (t, J = 6.1 Hz,
1H), 5.05 (s, 2H), 4.46 (d, J = 6.1 Hz, 2H).

13

C NMR (101 MHz, CDCl3) δ 166.46,

153.03, 146.43, 136.07, 135.70, 134.99, 133.83, 132.54, 132.45, 130.73, 129.03, 128.89,
128.87, 128.75, 124.72, 118.29, 117.99, 75.85, 39.21.
2,4-Dibromo-6-((2-nitrobenzamido)methyl)phenyl 2 -chlorobenzoate, 2.
N-(2-(Methoxy)-3,5-dibromobenzyl)-2-nitrobenzamide (354 mg, 0.681 mmol) was
dissolved in CH2Cl2 (4.54 mL, 0.15 M) and cooled to -78 °C in a dry ice/acetone bath.
BBr3 (65 µL, 0.681 mmol) was added dropwise and the mixture stirred for 3 h while the
temperature was kept between -20 and -60 °C. The reaction was quenched with sat.
23

NaHCO3 (25 mL) and was extracted with CH2Cl2 (50 mL). This organic layer was
washed with brine and then dried over Na2SO4. Purification via silica-gel column
chromatography (product elutes around 40% EtOAc) afforded 129.5 mg of the desired
product, 30.2% yield. 1H NMR (400 MHz, DMSO-d6) δ 9.25 (t, J = 6.2 Hz, 1H), 7.99 (d,
J = 8.0 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.70 – 7.56 (m, 3H), 7.34 (d, J = 2.2 Hz, 1H),
4.37 (d, J = 5.1 Hz, 2H).

13

C NMR (101 MHz, DMSO-d6) δ 166.33, 151.20, 147.18,

133.78, 133.02, 131.85, 131.14, 130.27, 130.03, 129.20, 124.28, 112.36, 110.97, 38.51.
ESI-MS calculated for C14H11Br2N2O4 428.9 [M+H], observed 428.9. This product was
reacted with 2-chlorobenzoyl chloride following the procedure for 2,4-dibromo-6-(2-((2nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate to provide the desired product,
72.1 mg (92% yield). Spectral data was consistent with previous report.19
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2chlorobenzoate, 3.
To 2-(3,5-dibromo-2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide22 (53.0 mg, 0.123
mmol) in CH2Cl2 (2.46 mL, 0.05 M) under N2 was added 2-chlorobenzoyl chloride (19
µL, 0.148 mmol), followed by Et3N (41 µL, 0.295 mmol) and then DMAP (1.5 mg,
0.0123 mmol). The mixture was allowed to stir overnight at room temperature and then
was diluted with CH2Cl2 (50 mL) and washed with HCl (25 mL, 1 M), sat. NaHCO3 (25
mL) and then brine (25 mL). After drying over Na2SO4, the material was purified via
silica-gel flash chromatography, affording 12.4 mg of the desired product (55% yield).
1

H-NMR (500MHz, CDCl3)  10.32 (s, 1H), 8.67 (dd, J = 8.5, 1.1 Hz, 1H), 8.17-8.10 (m,

2H), 7.81 (d, J = 2.2 Hz, 1H), 7.63-7.56 (m, 2H), 7.50-7.45 (m, 2H), 7.36-7.30 (m, 1H),
7.16 (ddd, J = 8.5, 7.3, 1.3 Hz, 1H), 3.78 (s, 2H).

C-NMR (125MHz, CDCl3)  169.8,

13

162.2, 146.6, 136.6, 136.2, 135.9, 135.1, 134.5, 134.2, 133.8, 132.6, 131.7, 130.7, 127.6,
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127.1, 125.9, 123.9, 122.4, 120.6, 118.9, 40.8. ESI-MS calculated for C21H14Br2ClN2O5,
566.89 [M+H], observed 566.82. HPLC purity 90.1%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3chlorobenzoate, 13.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 11.7 mg of the desired product (52% yield). 1H-NMR (500MHz,
CDCl3)  10.35 (s, 1H), 8.68 (d, J = 8.4 Hz, 1H), 8.15 (dd, J = 8.5, 1.3 Hz, 1H), 8.09-8.05
(m, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.79 (d, J = 2.2Hz, 1H), 7.63 (ddd, J = 8.5, 7.2, 1.0 Hz,
1H), 7.60-7.54 (m, 2H), 7.39 (t, J = 7.9 Hz, 1H), 7.18 (ddd, J = 8.4, 7.3, 1.1 Hz, 1H), 3.71
(s, 2H).

C-NMR (125MHz, CDCl3)  167.8, 162.6, 146.6, 136.4, 136.3, 135.8, 135.2,

13

134.6, 134.5, 133.8, 130.8, 130.6, 130.3, 129.7, 128.8, 126.0, 123.9, 122.2, 120.6, 118.8,
41.0. ESI-MS calculated for C21H14Br2ClN2O5, 566.89 [M+H], observed 566.90. HPLC
purity 92.2%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4chlorobenzoate, 14.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 15.8 mg of the desired product (70% yield). 1H-NMR (500MHz,
CDCl3)  10.33 (s, 1H), 8.67 (dd, J = 8.5, 1.1 Hz, 1H), 8.15 (dd, J = 8.5, 1.5 Hz, 1H),
8.08-8.03 (m, 2H), 7.79 (d, J = 2.2 Hz, 1H), 7.62 (ddd, J = 8.6, 7.2, 1.4 Hz, 1H), 7.57 (d,
J = 2.2 Hz, 1H), 7.43-7.37 (m, 2H), 7.18 (ddd, J = 8.5, 7.2, 1.2 Hz, 1H), 3.71 (s, 3H). 13CNMR (125MHz, CDCl3)  167.9, 163.0, 146.7, 141.2, 136.4, 136.2, 135.8, 134.5, 133.7,
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132.0, 130.8, 129.4, 126.4, 126.0, 123.9, 122.2, 120.5, 118.8, 41.0. ESI-MS calculated for
C21H14Br2ClN2O5, 566.89 [M+H], observed 566.80. HPLC purity 91.7%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2bromobenzoate, 15.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 14.3 mg of the desired product (63% yield). 1H-NMR (500MHz,
CDCl3)  10.32 (s, 1H), 8.68 (dd, J = 8.5, 1.0 Hz, 1H), 8.17-8.11 (m, 2H), 7.81 (d, J = 2.2
Hz, 1H), 7.71-7.66 (m, 1H), 7.63-7.57 (m, 2H), 7.41-7.36 (m, 2H), 7.16 (ddd, J = 8.5,
7.2, 1.2 Hz, 1H), 3.79 (s, 2H). 13C-NMR (125MHz, CDCl3)  167.8, 162.7, 146.6, 136.6,
136.1, 135.9, 135.1, 134.5, 134.1, 133.8, 132.7, 130.7, 129.5, 127.6, 126.0, 123.9, 123.1,
122.4, 120.6, 118.8, 40.8. ESI-MS calculated for C21H14Br3N2O5, 610.84 [M+H],
observed 610.79. HPLC purity 91.2%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3bromobenzoate, 16.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 16.3 mg of the desired product (67% yield). 1H-NMR (500MHz,
CDCl3)  10.35 (s, 1H), 8.68 (dd, J = 8.5, 1.0 Hz, 1H), 8.22 (t, J = 1.0 Hz, 1H), 8.15 (dd,
J = 8.4, 1.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.79 (d, J = 2.2 Hz, 1H), 7.75-7.71 (m,
1H), 7.64-7.61 (m, 1H), 7.57 (d, J = 2.1 Hz, 1H), 7.33 (t, J = 8.7 Hz, 1H), 7.18 (t, J = 8.6
Hz, 1H), 3.71 (s, 2H).

13

C-NMR (125MHz, CDCl3)  167.8, 162.5, 146.6, 137.5, 136.3,

135.8, 134.5, 133.8, 133.5, 130.8, 130.5, 129.9, 129.3, 126.0, 124.0, 123.0, 122.2, 120.6,
26

118.7, 41.0. ESI-MS calculated for C21H14Br3N2O5, 610.84 [M+H], observed 610.81.
HPLC purity 98.1%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4bromobenzoate, 17.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 15.1 mg of the desired product (62% yield). 1H-NMR (500MHz,
CDCl3)  10.34 (s, 1H), 8.68 (dd, J = 8.5, 0.9 Hz, 1H), 8.16 (dd, J = 8.4, 1.0 Hz, 1H),
7.98 (d, J = 8.5 Hz), 7.79 (d, J = 2.3 Hz, 1H), 7.65-7.54 (m, 3H), 7.18 (t, J = 8.4 Hz, 1H),
3.71 (s, 2H).

13

C-NMR (125MHz, CDCl3)  167.9, 163.1, 146.7, 136.3, 135.8, 134.5,

133.7, 132.4, 132.1, 130.8, 130.0, 126.8, 126.0, 123.9, 122.2, 120.6, 118.8, 41.0. ESI-MS
calculated for C21H14Br3N2O5, 610.84 [M+H], observed 610.82. HPLC purity 93.6%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2fluorobenzoate, 18.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 15.4 mg of the desired product (70% yield). 1H-NMR (500MHz,
CDCl3)  10.32 (s, 1H), 8.67 (dd, J = 8.4, 0.9 Hz, 1H), 8.15 (dd, J = 8.5, 1.0 Hz, 1H),
8.06 (dt, J = 8.4, 0.9 Hz, 1H), 7.79 (d, J = 2.2 Hz, 1H), 7.64-7.55 (m, 2H), 7.24-7.11
(m,2H), 3.75 (s, 2H).

13

C-NMR (125MHz, CDCl3) 167.8, 163.7, 161.6, 161.2, 161.1,

136.3, 136.2, 136.2, 135.8, 134.5, 133.7, 133.0, 130.7, 125.9, 124.5, 124.5, 123.9, 122.4,
120.5, 118.8, 117.6, 117.4, 116.7, 116.6, 40.8. ESI-MS calculated for C21H14Br2FN2O5,
550.93 [M+H], observed 550.91. HPLC purity 95.8%.
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2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4fluorobenzoate, 19.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 12.7 mg of the desired product (58% yield). 1H-NMR (500MHz,
CDCl3)  10.33 (s, 1H), 8.67 (d, J = 8.3 Hz, 1H), 8.20-8.11 (m, 2H), 7.79 (d, J = 1.9 Hz,
1H), 7.62 (t, J = 8.4 Hz, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.18 (t, J = 8.4 Hz, 1H), 7.14-7.07
(m, 2H), 3.71 (s, 2H).

C-NMR (125MHz, CDCl3) 167.9, 167.8, 165.7, 162.8, 146.7,

13

136.5, 136.2, 135.7, 134.5, 133.7, 133.5, 133.4, 130.8, 126.0, 124.2, 123.9, 122.2, 120.5,
118.8, 116.4, 116.2, 40.9. ESI-MS calculated for C21H14Br2FN2O5, 550.93 [M+H],
observed 550.90. HPLC purity 92.0%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2iodobenzoate, 20.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 9.5 mg of the desired product (77% yield). 1H NMR (400 MHz,
CDCl3) δ 10.33 (s, 1H), 8.70 (dt, J = 8.5, 1.2 Hz, 1H), 8.23 – 8.13 (m, 2H), 8.05 (dt, J =
7.9, 1.2 Hz, 1H), 7.82 (dd, J = 2.4, 1.1 Hz, 1H), 7.65 – 7.57 (m, 2H), 7.47 – 7.39 (m, 1H),
7.26 – 7.13 (m, 2H), 3.80 (d, J = 1.0 Hz, 2H).

13

C NMR (101 MHz, CDCl3) δ 167.72,

162.75, 142.23, 141.98, 136.02, 135.78, 135.03, 134.46, 134.11, 133.74, 132.34, 132.11,
130.68, 129.74, 128.30, 125.88, 123.80, 122.38, 120.54, 118.79, 40.81. ESI-MS
calculated for C21H14Br2IN2O5, 658.83 [M+H], observed 658.90. HPLC purity 96.8%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2methylbenzoate, 21.
28

Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 16.0 mg of the desired product (61% yield). 1H-NMR (500MHz,
CDCl3)  10.33 (s, 1H), 8.68 (d, J = 8.4 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 8.13 (dd, J =
8.4, 0.9 Hz, 1H), 7.80 (d, J = 2.0 Hz, 1H), 7.60 (t, J = 8.2 Hz, 1H), 7.57 (d, J = 1.9 Hz,
1H), 7.44 (t, J = 8.2 Hz, 1H), 7.27-7.13 (m, 2H), 3.73 (s, 2H), 2.53 (s, 3H).

13

C-NMR

(125MHz, CDCl3) 168.0, 163.9, 147.0, 142.4, 136.5, 136.1, 135.7, 134.5, 133.7, 133.7,
132.3, 131.8, 130.9, 126.8, 126.2, 125.9, 123.8, 122.2, 120.2, 119.1, 41.0, 22.1. ESI-MS
calculated for C22H17Br2N2O5, 546.95 [M+H], observed 546.89. HPLC purity 96.4%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3methylbenzoate, 22.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 15.8 mg of the desired product (72% yield). 1H-NMR (500MHz,
CDCl3)  10.33 (s, 1H), 8.70 (dd, J = 8.4, 0.8 Hz, 1H), 8.13 (dd, J = 8.4, 0.9 Hz), 7.947.89 (m, 2H), 7.78 (d, J = 2.1, Hz, 1H), 7.61 (t, J = 8.2 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H),
7.43-7.37 (m, 1H), 7.30 (t, J = 8.4 Hz, 1H), 7.16 (t, J = 8.4 Hz, 1H), 3.71 (s, 2H), 2.33 (s,
3H).

C-NMR (125MHz, CDCl3)  167.9, 163.9, 146.9, 138.9, 136.4, 136.2, 135.7,

13

135.4, 134.6, 133.7, 131.1, 130.9, 128.8, 127.9, 127.8, 125.9, 123.8, 122.2, 120.3, 118.9,
40.9, 21.4. ESI-MS calculated for C22H17Br2N2O5, 546.95 [M+H], observed 546.96.
HPLC purity 94.4%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4methylbenzoate, 23.
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Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 17.1 mg of the desired product (78% yield). 1H-NMR (500MHz,
CDCl3)  10.32 (s, 1H), 8.69 (dd, J = 8.4, 0.9 Hz, 1H), 8.13 (dd, J = 8.4, 0.9 Hz, 1H),
8.00 (d, J = 8.5 Hz, 2H), 7.78 (d, J = 2.1 Hz, 1H), 7.61 (t, J = 8.3 Hz, 1H), 7.56 (d, J =
2.1 Hz, 1H), 7.20 (d, J = 8.5 Hz, 2H), 7.17 (t, J = 8.4 Hz, 1H), 3.71 (s, 2H), 2.40 (s, 3H).
C-NMR (125MHz, CDCl3)  168.0, 163.8, 146.9, 145.6, 136.4, 136.2, 135.7, 134.6,

13

133.6, 131.0, 130.8, 129.6, 125.9, 125.1, 123.8, 122.3, 120.2, 118.9, 40.9, 22.1. ESI-MS
calculated for C22H17Br2N2O5, 546.95 [M+H], observed 546.92. HPLC purity 91.7%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2methoxybenzoate, 24.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 10 mg of the desired product (65.6% yield). 1H NMR (400 MHz,
CDCl3) δ 10.29 (s, 1H), 8.70 (dd, J = 8.5, 1.3 Hz, 1H), 8.15 (dd, J = 8.4, 1.6 Hz, 1H),
8.02 (dd, J = 7.8, 1.8 Hz, 1H), 7.80 (d, J = 2.3 Hz, 1H), 7.66 – 7.47 (m, 3H), 7.21 – 7.11
(m, 1H), 7.03 – 6.91 (m, 2H), 3.86 (s, 3H), 3.80 (s, 2H). 13C NMR (101 MHz, CDCl3) δ
168.09, 162.72, 160.18, 146.93, 136.61, 135.95, 135.60, 135.16, 134.51, 133.54, 132.69,
130.81, 125.82, 123.71, 122.36, 120.40, 120.06, 119.02, 117.52, 112.24, 56.10, 40.65.
ESI-MS calculated for C22H17Br2N2O6, 562.94 [M+H], observed 563.07. HPLC purity
89.9%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2nitrobenzoate, 25.
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Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 14.4 mg of the desired product (19.1% yield). 1H NMR (400 MHz,
CDCl3) δ 10.35 (s, 1H), 8.68 (dd, J = 8.6, 1.3 Hz, 1H), 8.13 (dd, J = 8.5, 1.2 Hz, 1H),
8.10 (dd, J = 7.4, 1.6 Hz, 1H), 8.01 (dd, J = 7.8, 1.4 Hz, 1H), 7.79 (d, 1H), 7.77 – 7.69
(m, 2H), 7.63 (d, 1H), 7.62 – 7.56 (m, 1H), 7.20 – 7.12 (m, 1H), 3.96 (s, 2H). 13C NMR
(101 MHz, CDCl3) δ 167.90, 162.39, 147.98, 145.87, 136.78, 135.86, 135.52, 134.37,
134.16, 133.47, 132.80, 131.18, 130.53, 126.30, 125.74, 124.55, 123.71, 122.51, 120.82,
118.26, 39.85. ESI-MS calculated for C21H14Br2N3O7, 577.92 [M+H], observed 577.79.
HPLC purity 91.1%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,6 dichlorobenzoate, 27.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 18.6 mg of the desired product (78% yield). 1H-NMR (500MHz,
CDCl3)  10.32 (s, 1H), 8.70 (d, J = 8.4 Hz, 1H), 8.16 (dd, J = 8.4, 1.0 Hz, 1H), 7.83 (d, J
= 2.1 Hz, 1H), 7.64-7.57 (m, 2H), 7.41-7.31 (m, 2H), 7.16 (t, J = 8.4 Hz, 1H), 3.98 (s,
2H).

C-NMR (125MHz, CDCl3)  167.9, 161.9, 146.1, 136.6, 136.3, 136.2, 134.5,

13

134.1, 133.0, 132.2, 131.2, 130.5, 128.9, 126.0, 123.9, 122.3, 121.1, 118.6, 40.5. ESI-MS
calculated for C21H12Br2Cl2N2O5, 600.86 [M+H], observed 600.99. HPLC purity 91.2%.
2-(3,5-Dibromo-2-((2,6-dichlorobenzyl)oxy)phenyl) -N-(2nitrophenyl)acetamide, 28.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
31

chloride, affording 33.26 mg of the desired product (13.7% yield). 1H NMR (400 MHz,
CDCl3) δ 10.13 (s, 1H), 8.62 (dd, J = 8.6, 1.3 Hz, 1H), 8.13 (dd, J = 8.5, 1.6 Hz, 1H),
7.68 (d, J = 2.4 Hz, 1H), 7.59 – 7.51 (m, 1H), 7.34 (d, J = 2.4 Hz, 1H), 7.25 – 7.21 (m,
2H), 7.17 – 7.07 (m, 2H), 5.45 (s, 2H), 3.54 (s, 2H).

C NMR (101 MHz, CDCl3) δ

13

168.67, 153.71, 137.34, 136.56, 136.06, 135.91, 134.66, 133.49, 132.13, 131.17, 131.00,
128.81, 125.79, 123.52, 122.35, 118.51, 117.84, 70.16, 39.81. ESI-MS calculated for
C21H15Br2Cl2N2O4, 586.87 [M+H], observed 586.76. HPLC purity 90.1%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl benzoate, 29.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 7.3 mg of the desired product (62.1% yield). 1H NMR (400 MHz,
CDCl3) δ 10.34 (s, 1H), 8.70 (dd, J = 8.5, 1.3 Hz, 1H), 8.18 – 8.12 (m, 3H), 7.81 (d, J =
2.2 Hz, 1H), 7.67 – 7.57 (m, 3H), 7.49 – 7.41 (m, 2H), 7.22 – 7.15 (m, 1H), 3.74 (s, 2H).
C NMR (101 MHz, CDCl3) δ 167.85, 163.71, 136.07, 135.65, 134.50, 134.45, 133.57,

13

130.85, 130.64, 128.87, 127.94, 125.86, 123.76, 122.23, 120.28, 40.83.

ESI-MS

calculated for C21H14Br2N2O5, 532.93 [M+H], observed 532.98. HPLC purity 90.0%.
2,4-Dibromo-6-(2-((2-nitrophenyl)amino )-2-oxoethyl)phenyl 2-bromo-4fluorobenzoate, 26.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate acid
chloride, affording 9.5 mg of the desired product (11% yield). 1H NMR (400 MHz,
CDCl3) δ 10.34 (s, 1H), 8.69 (dd, J = 8.5, 1.3 Hz, 1H), 8.17 (dd, J = 8.5, 1.5 Hz, 1H),
7.99 – 7.92 (m, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.63 – 7.58 (m, 2H), 7.45 – 7.30 (m, 2H),
7.22 – 7.15 (m, 1H), 3.81 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.64, 161.84, 146.40,
32

138.59, 136.55, 136.08, 135.85, 134.37, 133.80, 131.53, 130.52, 128.88, 128.80, 127.94,
125.89, 123.88, 122.26, 120.84, 120.60, 118.68, 40.80. ESI-MS calculated for
C21H12Br3FN2O5, 628.84 [M+H], observed 629.18. HPLC purity 87.6%.
2-(3,5-Dibromo-2-((2-chlorobenzoyl)oxy)phenyl)acetic acid.
To a solution of methyl 2-(3,5-dibromo-2-hydroxyphenyl)acetate (2.902g, 8.96mmol) in
CH2Cl2 (59mL) at room temperature was added Et3N (2.99mL, 21.49mmol), 2chlorobenzoyl chloride (1.248g, 9.85mmol) and DMAP (0.109g, 0.896mmol). The
mixture was allowed to react overnight and was diluted with CH2Cl2, quenched with 1M
HCl, washed with sat. NaHCO3 and brine, dried over Na2SO4, concentrated and purified
by

flash

column

chromatography

to

provide

2,4-dibromo-6-(2-methoxy-2-

oxoethyl)phenyl 2-chlorobenzoate (2.91g, 70%). 1H NMR (400 MHz, CDCl3) δ 8.198.16 (m, 1H), 7.74 (d, J = 2.2 Hz, 1H), 7.56-7.72 (m, 2H), 7.50-7.48 (m, 1H), 7.44-7.39
(m, 1H), 3.64 (s, 3H), 3.62 (s, 2H). The above methyl ester, 2,4-dibromo-6-(2-methoxy2-oxoethyl)phenyl 2-chlorobenzoate (1.823g, 3.94mmol) was dissolved in 1,2dichloroethane (39.4mL) and was treated with trimethyltinhydroxide (1.425g,
7.88mmol). The mixture was heated to 80oC and was monitored by TLC to confirm the
consumption of the starting material. After 2h the reaction was diluted with CHCl 3,
washed with 1M HCl and sat. NaCl, dried over Na2SO4, concentrated and purified by
flash column chromatography using a gradient of 20% EtOAc/hexanes to 100% EtOAc to
provide 2-(3,5-dibromo-2-((2-chlorobenzoyl)oxy)phenyl)acetic acid as a white solid
(1.045g, 59%). 1H NMR (400 MHz, CDCl3) δ 8.18-8.14 (m, 1H), 7.76 (d, J = 2.3 Hz,
1H), 7.55-7.52 (m, 2H), 7.50 (d, J = 2.2 Hz, 1H), 7.40 (ddd, J = 7.8, 5.6, 3.0 Hz, 1H),
3.65 (s, 2H).
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2,4-Dibromo-6-(2-((3-nitrophenyl)amino)-2-oxoethyl)phenyl 2chlorobenzoate, 30.
To a solution of 2-(3,5-dibromo-2-((2-chlorobenzoyl)oxy)phenyl)acetic acid (0.181g,
0.4035mmol) in ACN (8.07mL) was added 3-nitroaniline (0.0613g, 0.4439mmol)
followed by EDC (0.1423g, 0.807mmol) and DMAP (0.0049g, 0.0403mmol). The
resulting mixture was allowed to react at room temperature overnight and was
concentrated to dryness. The residue was suspended in CHCl3, washed with 1M HCl, sat.
NaHCO3 and brine, dried over Na2SO4 and concentrated. The residue was purified by
flash column chromatography using a gradient of hexanes to EtOAc, affording 1.1 mg of
the desired product (0.5% yield). 1H NMR (400 MHz, CDCl3) δ 8.41 (t, J = 2.2 Hz, 1H),
8.26 (d, J = 7.4 Hz, 1H), 8.02 (s, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 8.1 Hz, 1H),
7.81 (d, J = 2.3 Hz, 1H), 7.62 (d, J = 2.3 Hz, 1H), 7.60 – 7.53 (m, 2H), 7.51 – 7.38 (m,
2H), 3.74 (s, 2H).

13

C NMR (101 MHz, CDCl3) δ 167.29, 164.52, 148.63, 145.90,

138.97, 135.78, 135.38, 134.75, 133.24, 132.76, 131.92, 131.08, 129.80, 127.30, 127.00,
125.52, 121.07, 119.13, 118.63, 114.70, 39.55.. ESI-MS calculated for C21H14Br2ClN2O5,
566.89 [M+H], observed 566.95. HPLC purity 91.3%.
2,4-Dibromo-6-(2-((4-nitrophenyl)amino )-2-oxoethyl)phenyl 2chlorobenzoate, 31.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((3-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate amine,
affording 3.5 mg of the desired product (1.4% yield). 1H NMR (400 MHz, CDCl3) δ 8.26
(dd, J = 8.1, 1.5 Hz, 1H), 8.20 – 8.15 (m, 2H), 8.14 (s, 1H), 7.81 (d, J = 2.3 Hz, 1H), 7.74
– 7.67 (m, 2H), 7.64 – 7.54 (m, 3H), 7.50 – 7.42 (m, 1H), 3.74 (s, 2H).

13

C NMR (101

MHz, CDCl3) δ 167.37, 164.71, 145.84, 143.77, 143.73, 135.85, 135.35, 134.81, 133.17,
34

132.76, 131.93, 130.93, 127.32, 127.00, 125.08, 121.14, 119.31, 118.63, 39.64. ESI-MS
calculated for C21H14Br2ClN2O5, 566.89 [M+H], observed 566.86. HPLC purity 94.8%.
2,4-Dibromo-6-(2-oxo-2-(pyridin-2-ylamino)ethyl)phenyl 2chlorobenzoate, 32.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((3-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate amine,
affording 24.9 mg of the desired product (22% yield). 1H NMR (400 MHz, CDCl3) δ 8.27
– 8.19 (m, 2H), 8.19 – 8.10 (m, 2H), 7.77 (d, J = 2.3 Hz, 1H), 7.70 – 7.64 (m, 1H), 7.58
(d, J = 2.3 Hz, 1H), 7.53 – 7.48 (m, 2H), 7.40 – 7.32 (m, 1H), 7.05 – 6.99 (m, 1H), 3.73
(s, 2H). 13C NMR (101 MHz, CDCl3) δ 167.23, 162.64, 151.12, 147.96, 146.34, 138.49,
135.47, 135.01, 134.05, 133.44, 132.56, 131.66, 131.15, 127.73, 127.03, 120.48, 120.20,
118.56, 114.21, 39.73. ESI-MS calculated for C20H14Br2ClN2O3, 522.91 [M+H],
observed 522.97. HPLC purity 98.3%.
2,4-Dibromo-6-(2-((2,3-difluorophenyl)amino )-2-oxoethyl)phenyl 2chlorobenzoate, 33.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((3-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate amine,
affording 24.9 mg of the desired product (41% yield). 1H NMR (400 MHz, Acetone-d6) δ
9.17 (s, 1H), 8.11 (dd, J = 7.9, 1.6 Hz, 1H), 7.80 (t, J = 7.4 Hz, 1H), 7.76 (d, J = 2.3 Hz,
1H), 7.65 (d, J = 2.3 Hz, 1H), 7.57 – 7.46 (m, 2H), 7.38 – 7.31 (m, 1H), 7.03 – 6.94 (m,
1H), 6.94 – 6.85 (m, 1H), 3.86 (s, 2H).

13

C NMR (101 MHz, CDCl3) δ 167.08, 162.99,

146.01, 135.52, 135.05, 134.31, 133.18, 133.15, 132.57, 131.73, 131.12, 127.83, 127.46,
127.13, 124.21, 120.63, 118.48, 117.08, 112.62, 112.45, 39.66. ESI-MS calculated for
C21H13Br2ClF2NO3, 557.89 [M+H], observed 558.09. HPLC purity 92.3%.
35

2,4-Dibromo-6-(2-((4,5-difluoro-2-nitrophenyl)amino)-2-oxoethyl)phenyl
2-chlorobenzoate, 34.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((3-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate amine,
affording 36.7 mg of the desired product (16% yield). 1H NMR (400 MHz, CDCl3) δ
10.41 (s, 1H), 8.74 (dd, J = 12.6, 7.5 Hz, 1H), 8.14 (dd, J = 7.9, 0.9 Hz, 1H), 8.07 (dd, J =
10.1, 7.9 Hz, 1H), 7.85 (d, J = 2.3, 0.7 Hz, 1H), 7.59 (d, 1H), 7.55 – 7.49 (m, 2H), 7.41 –
7.35 (m, 1H), 3.81 (s, 2H).

13

C NMR (101 MHz, CDCl3) δ 167.90, 162.12, 146.58,

136.02, 135.00, 134.18, 133.71, 132.55, 131.71, 130.14, 127.47, 127.05, 120.64, 118.93,
115.14, 114.93, 111.01, 110.76, 40.75. ESI-MS calculated for C21H12Br2ClN3O5, 602.88
[M+H], observed 602.77. HPLC purity 97.0%.
2,4-Dibromo-6-(2-oxo-2-(pyrimidin -4-ylamino)ethyl)phenyl 2 chlorobenzoate, 35.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((3-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate amine,
affording 15.2 mg of the desired product (13% yield). 1H NMR (400 MHz, CDCl3) δ 8.83
(s, 1H), 8.61 (s, 1H), 8.34 (s, 1H), 8.21 – 8.14 (m, 1H), 8.10 (dd, J = 5.8, 1.2 Hz, 1H),
7.80 (d, J = 2.4 Hz, 1H), 7.57 (d, J = 2.4 Hz, 1H), 7.55 – 7.52 (m, 2H), 7.42 – 7.36 (m,
1H), 3.76 (s, 2H).

13

C NMR (101 MHz, CDCl3) δ 168.19, 162.98, 158.59, 158.49,

156.87, 146.25, 135.79, 135.03, 134.27, 133.32, 132.57, 131.73, 130.43, 127.54, 127.12,
120.67, 118.71, 110.42, 39.79. ESI-MS calculated for C19H13Br2ClN3O3, 523.90 [M+H],
observed 523.92. HPLC purity 94.4%.
2,4-Dibromo-6-(2-((3-nitropyridin -4-yl)amino)-2-oxoethyl)phenyl 2chlorobenzoate, 36.
36

Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((3-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate amine,
affording 4.1 mg of the desired product (5.8% yield). 1H NMR (400 MHz, CDCl3) δ
10.50 (s, 1H), 9.33 (s, 1H), 8.67 (s, 2H), 8.13 (dd, 1H), 7.86 (d, J = 2.2 Hz, 1H), 7.59 (d,
J = 2.3 Hz, 1H), 7.56 – 7.47 (m, 2H), 7.41 – 7.34 (m, 1H), 3.84 (s, 2H). 13C NMR (101
MHz, CDCl3) δ 168.31, 162.10, 156.31, 155.69, 136.16, 134.22, 133.69, 132.54, 131.72,
129.85, 129.27, 128.07, 127.41, 127.06, 120.70, 118.99, 114.62, 40.90. ESI-MS
calculated for C20H13Br2ClN3O5, 567.89 [M+H], observed 567.82. HPLC purity 89.8%.
(S)-2,4-Dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran -3yl)amino)ethyl)phenyl 2 -chlorobenzoate, 37.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((3-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate using the appropriate amine,
affording 27.9 mg of the desired product (81% yield). 1H NMR (400 MHz, CDCl3) δ 8.21
(dd, J = 7.9, 1.2 Hz, 1H), 7.77 (dd, J = 2.3, 1.2 Hz, 1H), 7.59 – 7.53 (m, 3H), 7.47 – 7.40
(m, 1H), 6.18 (s, 1H), 4.55 – 4.35 (m, 2H), 4.29 – 4.14 (m, 1H), 3.61 (s, 2H), 2.76 – 2.61
(m, 1H), 2.16 – 1.99 (m, 1H).

13

C NMR (101 MHz, CDCl3) δ 174.76, 169.16, 135.45,

135.02, 134.32, 133.47, 132.70, 131.78, 131.23, 127.48, 127.21, 120.57, 118.45, 66.07,
49.53, 38.19, 29.81. ESI-MS calculated for C19H15Br2ClNO5, 529.90 [M+H], observed
529.85. HPLC purity 94.9%.
2,4-Dibromo-6-(picolinamidomethyl)phenyl 2 -chlorobenzoate, 38.
The required phenol, N-(3,5-dibromo-2-hydroxybenzyl)picolinamide was prepared in two
steps from (2-(benzyloxy)-3,5-dibromophenyl)methanamine and pyridine-2-carboxylic
acid as described for N-(3,5-dibromo-2-hydroxybenzyl)-2-nitrobenzamide, providing the
desired product (0.10g, 35%, two steps). 1H NMR (400 MHz, Chloroform-d) δ 9.88 (s,
37

1H), 8.84 – 8.79 (m, 1H), 8.55 (d, J = 4.7 Hz, 1H), 8.20 (d, J = 7.8 Hz, 1H), 7.87 (dt, J =
7.7, 1.7 Hz, 1H), 7.59 (d, J = 2.4 Hz, 1H), 7.47 (ddd, J = 7.6, 4.7, 1.2 Hz, 1H), 7.29 (d, J
= 2.4 Hz, 1H), 4.55 (d, J = 6.8 Hz, 2H). This product was reacted with 2-chlorobenzoyl
chloride

according

to

the

procedure

provided

for

2,4-dibromo-6-((2

nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording 11.4 mg of the desired
product (38% yield). 1H NMR (400 MHz, CDCl3) δ 8.54 (dd, J = 4.7, 1.4 Hz, 1H), 8.45
(s, 1H), 8.21 (dd, J = 7.8, 1.1 Hz, 1H), 8.15 (dd, J = 7.8, 1.1 Hz, 1H), 7.84 (td, J = 7.8,
1.8 Hz, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.58 (d, J = 2.3 Hz, 1H), 7.54 (d, 2H), 7.46 – 7.39
(m, 2H), 4.66 (d, J = 6.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 164.56, 162.48, 149.41,
148.35, 145.84, 137.52, 135.04, 134.94, 133.99, 132.61, 131.78, 131.65, 127.89, 127.00,
126.59, 122.51, 120.33, 118.12, 38.74. ESI-MS calculated for C20H14Br2ClN2O5, 522.91
[M+H], observed 523.04. HPLC purity 97.7%.
2,4-Dibromo-6-((2,3-difluorobenzamido)methyl)phenyl 2 -chlorobenzoate,
39.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-((2

nitrobenzamido)methyl)phenyl 2-chlorobenzoate from 2-chlorobenzoyl chloride and N(3,5-dibromo-2-hydroxybenzyl)-2,3-difluorobenzamide, affording 7.9 mg of the desired
product (18% yield). 1H NMR (400 MHz, CDCl3) δ 8.21 (dd, 1H), 7.81 – 7.73 (m, 2H),
7.62 (d, J = 2.3 Hz, 1H), 7.57 – 7.53 (m, 2H), 7.46 – 7.40 (m, 1H), 7.36 – 7.27 (m, 1H),
7.21 – 7.14 (m, 1H), 7.04 (t, J = 11.4 Hz, 1H), 4.66 (s, 2H). 13C NMR (101 MHz, CDCl3)
δ 162.73, 162.47, 145.94, 135.36, 134.98, 134.44, 134.12, 132.55, 132.25, 131.69,
127.75, 127.09, 126.60, 126.57, 124.78, 124.72, 120.83, 120.65, 120.43, 118.16, 39.40.
ESI-MS calculated for C21H13Br2ClF2NO3, 557.89 [M+H], observed 557.77. HPLC
purity 90.0%.
38

2,4-Dibromo-6-((pyrimidine-4-carboxamido)methyl)phenyl 2 chlorobenzoate, 40.
The required phenol, N-(3,5-dibromo-2-hydroxybenzyl)pyrimidine-4-carboxamide was
prepared in two steps from (2-(benzyloxy)-3,5-dibromophenyl)methanamine and
pyrimidine-4-carboxylic acid as described for N-(3,5-dibromo-2-hydroxybenzyl)-2nitrobenzamide, providing the desired product (0.082g, 32%, two steps). 1H-NMR (400
MHz, Chloroform-d) δ 9.22 (s, 1H), 8.99 (d, J = 5.0 Hz, 1H), 8.82 – 8.74 (m, 1H), 8.10
(dd, J = 5.0, 1.4 Hz, 1H), 7.56 (d, J = 2.4 Hz, 1H), 7.32 (d, J = 2.4 Hz, 1H), 4.59 (d, J =
6.7 Hz, 2H). This product was reacted with 2-chlorobenzoyl chloride according to the
procedure

provided

for

2,4-dibromo-6-((2

nitrobenzamido)methyl)phenyl

2-

chlorobenzoate, affording 7.7 mg of the desired product (7.0% yield). 1H NMR (400
MHz, Chloroform-d) δ 9.22 (d, J = 1.4 Hz, 1H), 8.96 (d, J = 5.0 Hz, 1H), 8.38 (t, 1H),
8.20 (d, 1H), 8.06 (d, 1H), 7.76 (d, J = 2.3 Hz, 1H), 7.61 – 7.52 (m, 2H), 7.48 – 7.38 (m,
1H), 4.66 (d, J = 6.3 Hz, 2H).

13

C NMR (101 MHz, Chloroform-d) δ 162.91, 162.64,

159.41, 157.96, 155.96, 146.08, 135.49, 134.27, 134.21, 132.72, 132.17, 131.77, 127.84,
127.15, 126.84, 120.46, 118.87, 118.39, 39.10. ESI-MS calculated for C19H13Br2ClN3O3,
523.90 [M+H], observed 523.67. HPLC purity 92.4%.
2,4-Dibromo-6-(nicotinamidomethyl)phenyl 2 -chlorobenzoate, 41.
The required phenol, N-(3,5-dibromo-2-hydroxybenzyl)nicotinamide was prepared in two
steps from (2-(benzyloxy)-3,5-dibromophenyl)methanamine and nicotinic acid as
described for N-(3,5-dibromo-2-hydroxybenzyl)-2-nitrobenzamide, providing the desired
product (0.048g, 17%, two steps). 1H-NMR (400 MHz, Chloroform-d) δ 9.03-8.91 (m,
1H), 8.81-8.71 (m, 1H), 8.15 (d, J = 8.1 Hz, 1H), 7.61 (d, J = 2.3 Hz, 1H), 7.42 (dd, J =
7.8, 5.0 Hz, 1H), 7.31 (d, J = 2.4 Hz, 1H), 7.03 (bs, 1H), 4.59 (d, J = 6.4 Hz, 2H). This
39

product was reacted with 2-chlorobenzoyl chloride according to the procedure provided
for 2,4-dibromo-6-((2 nitrobenzamido)methyl)phenyl 2-chlorobenzoate, affording 4.2 mg
of the desired product (6.5% yield). 1H NMR (400 MHz, CDCl3) δ 8.97 (s, 1H), 8.71 (s,
1H), 8.21 (dd, 1H), 8.07 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 2.3 Hz, 1H), 7.62 (d, J = 2.3 Hz,
1H), 7.58 – 7.50 (m, 2H), 7.47 – 7.39 (m, 1H), 7.39 – 7.33 (m, 1H), 6.80 (t, 1H), 4.63 (s,
2H).

13

C NMR (101 MHz, CDCl3) δ 165.40, 163.37, 152.55, 148.24, 146.10, 135.58,

135.21, 135.00, 134.32, 132.79, 132.64, 131.74, 127.52, 127.17, 123.63, 120.52, 118.19,
39.50. ESI-MS calculated for C20H14Br2ClN2O5, 522.91 [M+H], observed 522.97. HPLC
purity 89.5%.
2,4-Dibromo-6-(picolinamidomethyl)phenyl 4 -(2,5-dioxo-2,5-dihydro-1Hpyrrol-1-yl)butanoate, 42.
Prepared

according

to

nitrobenzamido)methyl)phenyl

the

procedure

provided

2-chlorobenzoate

for

from

2,4-dibromo-6-((2
N-(3,5-dibromo-2-

hydroxybenzyl)picolinamide, affording 35.7 mg of the desired product (25.1% yield). 1H
NMR (400 MHz, CDCl3) δ 8.53 (dd, J = 4.8, 1.3 Hz, 1H), 8.41 (s, 1H), 8.19 (dd, J = 7.8,
1.2 Hz, 1H), 7.86 (td, J = 7.7, 1.7 Hz, 1H), 7.66 (d, J = 2.3 Hz, 1H), 7.53 (d, J = 2.3 Hz,
1H), 7.47 – 7.39 (m, 1H), 6.72 (s, 2H), 4.59 (d, J = 6.4 Hz, 2H), 3.68 (t, J = 6.7 Hz, 2H),
2.70 (t, J = 7.3 Hz, 2H), 2.10 – 1.98 (m, 2H).

13

C NMR (101 MHz, CDCl3) δ 170.94,

170.02, 164.39, 149.49, 148.32, 146.02, 137.56, 134.94, 134.82, 134.31, 132.05, 126.56,
122.53, 119.96, 118.15, 38.75, 36.98, 31.20, 23.79. ESI-MS calculated for
C21H18Br2N3O5, 549.96 [M+H], observed 549.92. HPLC purity 89.7%.
(S)-2-(3,5-Dibromo-2-hydroxyphenyl)-N-(2-oxotetrahydrofuran-3yl)acetamide.
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To a solution of 2-(3,5-dibromo-2-hydroxyphenyl)acetic acid (0.750g, 2.42mmol) and LHomoserine lactone hydrobromide (0.881g, 4.84mmol) in DMF (12.1mL) was added
HATU (1.103g, 2.90mmol) followed by i-Pr2NEt (1.3mL, 7.26mmol). The resulting
mixture was allowed to stir at room temperature overnight, was diluted with EtOAc,
washed with water, 1M HCl and brine, dried over Na2SO4 and concentrated to dryness.
The residue was purified by flash column chromatography using a gradient from hexanes
to EtOAc to provide the desired product (0.430g, 45%).

1

H-NMR (400 MHz,

Chloroform-d) δ 8.68 (s, 1H), 7.55 (d, J = 2.3 Hz, 1H), 7.21 (d, J = 2.3 Hz, 1H), 6.92 (d, J
= 6.1 Hz, 1H), 4.61-4.52 (m, 1H), 4.48 (t, J = 9.1 Hz, 1H), 4.36-4.25 (m, 1H), 3.62 (ABq,
ΔνAB = 11.3 Hz, JAB = 12.3 Hz, 2H), 2.85-2.75 (m, 1H), 2.25-2.11 m, 1H).
2,4-Dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl
4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoate, 43.
Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate from (S)-2-(3,5-dibromo-2hydroxyphenyl)-N-(2-oxotetrahydrofuran-3-yl)acetamide, affording 12.5 mg of the
desired product (61% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.67 (d, J = 2.3 Hz,
1H), 7.58 (d, J = 2.3 Hz, 1H), 7.14 (s, 1H), 6.77 (s, 2H), 4.59 – 4.48 (m, 1H), 4.44 (t, 1H),
4.32 – 4.21 (m, 1H), 3.77 – 3.64 (m, 2H), 2.89 – 2.79 (m, 1H), 2.84 – 2.67 (m, 2H), 2.20
– 2.01 (m, 2H).

13

C NMR (101 MHz, Chloroform-d) δ 175.30, 171.77, 170.42, 169.82,

134.90, 134.56, 134.06, 131.72, 120.02, 66.36, 49.73, 37.50, 36.68, 31.16, 30.62, 30.51,
23.69. ESI-MS calculated for C20H19Br2N2O7, 556.96 [M+H], observed 556.81. HPLC
purity 92.5%.
2,4-Dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl
3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoate, 44.
41

Prepared

according

to

the

procedure

provided

for

2,4-dibromo-6-(2-((2-

nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate from (S)-2-(3,5-dibromo-2hydroxyphenyl)-N-(2-oxotetrahydrofuran-3-yl)acetamide, affording 1.8 mg of the desired
product (17% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.68 (d, J = 2.2 Hz, 1H), 7.53
(d, J = 2.2 Hz, 1H), 6.75 (s, 1H), 4.60 – 4.48 (m, 1H), 4.46 (t, J = 9.1 Hz, 1H), 4.33 – 4.21
(m, 1H), 4.15 – 3.91 (m, 2H), 3.62 – 3.47 (m, 2H), 3.12 – 2.97 (m, 2H), 2.83 – 2.71 (m,
0H), 2.75 (s, 1H), 2.25 – 2.09 (m, 1H), 1.38 – 1.23 (m, 2H), 0.89 (d, J = 12.6 Hz, 1H).
C NMR (101 MHz, Chloroform-d) δ 175.23, 170.84, 169.52, 168.71, 146.18, 135.12,

13

134.60, 133.71, 131.50, 120.34, 118.19, 66.27, 49.62, 37.96, 33.58, 32.69, 31.85, 30.08,
29.87. ESI-MS calculated for C19H17Br2N2O7, 542.94 [M+H], observed 542.92. HPLC
purity 91.8%.
1.1. LasR Bioassay
The LasR reporter strain bioassay was performed as described previously with
modifications.23 Briefly, the assays were performed in E. coli strain BL21 DE3 Gold
(Agilent) carrying a plasmid containing lasR (maintained with 100 μg/mL ampicillin) and
a plasmid containing the rsaL promoter-driving expression of gfp (maintained with 50
μg/mL of kanamycin.) The reporter strain described above was kindly supplied by
Bonnie L. Bassler (Princeton University). This E. coli strain was grown overnight at 37oC
in Luria broth (LB) (Fisher) with the appropriate antibiotics. The overnight culture was
subcultured 1:40 for bioassay analysis. The native LasR agonist, N-3-oxo-dodecanoyl-Lhomoseriene lactone was used as a positive control for all agonist assays
(EC50=72.9±24.6nM) and was employed at a constant concentration of 50nM for all
antagonist assays. For agonists assays, maximal % activation is reported with respect to
N-3-oxo-dodecanoyl-L-homoseriene lactone set as 100% activation. For antagonism
42

assays,

the

previously

described

antagonist,

(S)-2-(4-bromophenyl)-N-(2-

oxotetrahydrofuran-3-yl) acetamide was used as the positive control for antagonism with
an IC50 of 26.31±15.7 M.8 Maximal % inhibition is reported with respect to (S)-2-(4bromophenyl)-N-(2-oxotetrahydrofuran-3-yl)

acetamide

set

as

100%

inhibition.

Compounds were added to the diluted overnight reporter strain in 96-well black
microplates with clear bottoms (Corning) at the starting concentrations described and
titrated by serial dilution. Plates were incubated with shaking at 37oC for 4-6h and were
evaluated for fluorescence (ex485/em538) and absorbance (A600) using a Molecular
Devices SpectraMax M5 microplate reader, or a FlexStation II 384 Molecular Devices
for fluorescence and a MultiSkan Spectrum for absorbance measurements. Dose-response
curves were fit to the data using standard nonlinear regression data fitting settings in
GraphPad Prism 6, no corrections for compound purity were made. All data points are
reported as mean with error describing the standard deviation.
Computational Modeling - Ligand Preparation
The triaryl series of ligands were prepared using first Maestro Elements then
Maestro 10.3. The 2D structures were draw using the 2D sketcher function in Maestro
Elements. The templates for the ligands were obtained from the Perez Lab. The 2D
sketches were then converted to 3D structures. Epik (an empirical pka prediction
program) was utilized to determine the charge of the molecule at pH 7.24 Finally, the 3D
structures were uploaded into the Maestro 10.3 and restrained minimization was run. This
function is used to relax and optimize the ligand structure.
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Protein Structure Preparation
The LasR crystal structure (PDB 3IX3) was prepared using the protein
preparation wizard function in Maestro. The charge state of preprocessed protein was
optimized at pH=7. Finally restrained minimization was performed to relax the protein
structure using OPLS3 force field.25
Ligand Docking
The individual ligands were docking using glide docking with extra precision
(XP) and default parameters.26,27 The receptor grid required for docking process was
generated using Van der Waals scaling factor of 1 and partial charge cutoff 0.25. Docking
was performed using a ligand-centered grid using OPLS3 force field. The Glide XP
Dock function performs a comprehensive systematic search for the best receptor
conformations and orientations to fit the ligand. To validate the docking method, the
crystal ligand of of 3-OXO-C12-HSL was docked back to the pocket. The small heavy
atom RMSD of 0.6Å between the docked pose and the crystal pose indicates the validity
of the docking method (see online supporting information, Figure S1).
Binding Energy Calculations and Decomposition Methods
Molecular Mechanism-General Born Surface Area (MM-GBSA) binding energies
were calculated on the complexes from the docking. OPLS3 force field25, VSGB 2.0
solvation model28 and the default Prime procedure was used for the MM-GBSA
calculation. The default procedure consists of three steps: Receptor alone (minimization),
Ligand alone (minimization), Receptor-ligand complex (minimization). The total binding
energy equation is: ΔG(bind) = Ecomplex(minimized) - ( Eligand(minimized) + Ereceptor(minimized). The
docked complex with the MM-GBSA binding energy is listed in Figure S2 of the online
supporting information. The residue breakdown of the ΔG(bind) were then used in
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combination with 2D interaction diagrams to identify and compare key residues within
the binding pocket. Note that since the binding entropy is not included in our analysis, the
binding energies by MMGBSA may over-estimate the binding free energy (i.e. the
binding affinity). But when the entropic term of different ligands are comparable, the
relative MMGBSA binding energies can be used to estimate the relative binding free
energy for ranking ligands.29 The correlation coefficient between the experimental
binding free energy (calculated from the EC50) and the MMGBSA binding energies is
0.5572, which is reasonable (see online supporting information, Figure S3).
Supplemental Figures

Figure 9. Comparison of the crystal pose and the Glide XP docked pose of 3-OXO-C12HSL.
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Unsigned MMGBSA (kcal/mol)
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R² = 0.5572
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Figure 10. Correlation plot between the experimental binding free energy, and the
calculated MMGBSA binding energy for the ligands in Figure S2.
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14.5

3

32

33

Nitro Group

Nitrogen

Florine

(kcal/mol)

(Kcal/mol)

(kcal/mol)

56 TYR

-4.9

-7.3

-6.0

60 TRP

-2.9

-2.4

64 TYR

-2.8

-3.9

73 ASP

-1.1

88 TRP
101 PHE

-5.8
-3.1

-2.8

105 ALA

-0.6

110 LEU

-2.0

-2.1

MMGBSA

-74.2

-80.5

-85.6

Experimental Value

-8.8

-7.2

-10.0

Figure 11. Key residues contributing to the binding energy for the 3 C ring analogs (3, 32
and 33).
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Figure 12. The superimposed ligands 33 (red) and 39 (black) in the binding pockets. The
bonding poses were very similar, except for the oxygen (yellow) within the amide which
showed a 180° flip.

1H-NMR

and 13C-NMR Sepctra for all Final Compounds and Key Intermediates

II-85, (2-(benzyloxy)-3,5-dibromophenyl)methanamine, SI3.
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N-(2-(benzyloxy)-3,5-dibromobenzyl)-2-nitrobenzamide, SI4.

50

N-(3,5-dibromo-2-hydroxybenzyl)-2-nitrobenzamide, SI5.

51

2-(2-methoxyphenyl)-N-(2-nitrophenyl)acetamide, SI6.

52

2-(2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide, SI7.
53

2-(3,5-dibromo-2-hydroxyphenyl)-N-(2-nitrophenyl)acetamide, SI8.

54

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, 3.

55

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3-chlorobenzoate, 13.

56

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-chlorobenzoate, 14.

57

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromobenzoate, 15.

58

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3-bromobenzoate, 16.

59

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-bromobenzoate, 17.

60

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-fluorobenzoate, 18.

61

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-fluorobenzoate, 19.

62

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-iodobenzoate, 20.

63

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-methylbenzoate, 21.

64

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 3-methylbenzoate, 22.

65

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 4-methylbenzoate, 23.

66

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-methoxybenzoate, 24.

67

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-nitrobenzoate, 25.

68

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2,6-dichlorobenzoate, 27.

89

2-(3,5-dibromo-2-((2,6-dichlorobenzyl)oxy)phenyl)-N-(2-nitrophenyl)acetamide, 28.

90

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl benzoate, 29.

91

2,4-dibromo-6-(2-((2-nitrophenyl)amino)-2-oxoethyl)phenyl 2-bromo-4-fluorobenzoate,

26.

92

2,4-dibromo-6-(2-((3-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, 30.

93

2,4-dibromo-6-(2-((4-nitrophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, 31.

94

2,4-dibromo-6-(2-oxo-2-(pyridin-2-ylamino)ethyl)phenyl 2-chlorobenzoate, 32.

95

2,4-dibromo-6-(2-((2,3-difluorophenyl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, 33.

96

2,4-dibromo-6-(2-((4,5-difluoro-2-nitrophenyl)amino)-2-oxoethyl)phenyl 2chlorobenzoate, 34.

97

2,4-dibromo-6-(2-oxo-2-(pyrimidin-4-ylamino)ethyl)phenyl 2-chlorobenzoate, 35.

98

2,4-dibromo-6-(2-((3-nitropyridin-4-yl)amino)-2-oxoethyl)phenyl 2-chlorobenzoate, 36.

99

(S)-2,4-dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl
chlorobenzoate, 37.

100

2,4-dibromo-6-(picolinamidomethyl)phenyl 2-chlorobenzoate, 38.

101

2,4-dibromo-6-((2,3-difluorobenzamido)methyl)phenyl 2-chlorobenzoate, 39.

102

2,4-dibromo-6-((pyrimidine-4-carboxamido)methyl)phenyl 2-chlorobenzoate, 40.

103

2,4-dibromo-6-(nicotinamidomethyl)phenyl 2-chlorobenzoate, 41.

104

2,4-dibromo-6-(picolinamidomethyl)phenyl 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1yl)butanoate, 42.

105

2,4-dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl 4-(2,5-dioxo2,5-dihydro-1H-pyrrol-1-yl)butanoate, 43.

106

2,4-dibromo-6-(2-oxo-2-((2-oxotetrahydrofuran-3-yl)amino)ethyl)phenyl 3-(2,5-dioxo-

2,5-dihydro-1H-pyrrol-1-yl)propanoate, 44.
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Chapter 2A
New Reaction Methodology
Introduction to New Reaction Development
Synthetic methodologies enabling the oxidative cleavage of carbon-carbon single
bonds is an area of considerable recent interest. The development of methodologies to
achieve this transformation would be anticipated to be of significant utility by expanding
substrate scope for oxidative C-C functionalization reactions in academic and industrial
applications. Due to the high activation energy for this transformation and the ubiquitous
nature of C-C bonds strategies that achieve selective cleavages remain challenging. To
overcome these challenges several methodologies have been developed employing
strained scaffolds, chelation assisted reactions and adjacent keto functionality. Here we
report a general strategy for the synthesis of carboxylic acid derivatives by oxidative
cleavage of methyl ketones.
Aromatic carboxylic acid derivatives are prevalent structural motifs in drug
molecules and materials. Synthetic access to these compounds is most commonly
achieved by initial carboxylation of the corresponding arene, requiring strong oxidants
(e.g. KMnO4, chromium-based oxidants) and harsh reaction conditions. Preparation of
carboxylic acid derivatives requires a subsequent transformation of the carboxylic acid.
Aromatic methyl ketones serve as an attractive alternative to aromatic carboxylic acids as
they are readily available and can be efficiently prepared by acylation. Conversion of this
alternative substrate requires the oxidative cleavage of a C-C single bond. The most
widely employed methodology to achieve this transformation, the well-known haloform
reaction allows ready access to the corresponding carboxylic acids however does not
116

allow for the direct assembly of other carboxylic acid derivatives. Hence, a reaction
enabling direct conversion of aromatic methyl ketones to a diverse array of carboxylic
acid derivatives would be desirable.
Inspired by the reliability of the well-established haloform reaction and based on
early industrial studies on the reactivity of acetyl nitrite, we envisioned a process
enabling the net oxidative C-C bond cleavage of aromatic methyl ketones. Analogous to
the haloform reaction this process was anticipated to proceed via a series of sequential αnitration reactions and subsequent nucleophilic displacement of an activated di- or trinitromethane. Contrasting the haloform reaction, in which the base (e.g. KOH) typically
serves as nucleophile forming carboxylic acids we envisioned the ability to easily
modulate the nature of the second nucleophile to allow direct access to a diverse array of
carboxylic acid derivatives.
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Reaction Optimization

Table 4

Optimization of the reaction changing stoichiometry and solvents, testing each reaction
by percent conversion.

EQ HNO3

EQ Ac2O

Solvent
(0.5 M)

Percent
Conversion
(by NMR)

1

1

AcOH

2%

2

1

AcOH

15%

3

3

AcOH

42%

6

3

AcOH

61%

6

3

THF

46%

6

3

DMSO

51%

6

3

ACN

83%

6

3

DMF

0%
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H
H

H
H

2 hr
22% NMR
conversion

4 hr
38% NMR
conversion

8 hr
56% NMR
conversion

16 hr
83% NMR
conversion
Figure 13. Percent conversion was calculated based on H’NMR, as starting material was
converted to intermediate product.

The full optimization of the reaction can be seen in Table 4 and Figure 13 as the
equivalents of each reactant is changed as well as the solvent being altered. As the time
of the reaction was increased, we see the greatest percent conversion at 16 hours as the
starting material transitions into intermediate, as determined by H’NMR. This
intermediate was completely isolated and characterized. Once the reaction was ran past
16 hours, no increase in conversion was seen. The overall reaction was settled at 6 EQ of
nitric acid, 3 EQ of acetic anhydride, and acetonitrile as solvent.
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Figure 14. Scope of the Nucleophile.

Figure 15. Scope of the Electrophile
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Figure 16. Heterocycle Synthesis

The overall scope of the various Nucleophiles can be seen in Figure 14 and Figure
16. The reaction worked very successfully with both Oxygen and Nitrogen based
nucleophiles of various kinds. The reaction even has some success when using electron
poor nucleophiles such as Molecules 8 and 10, but at much lower yields compared to the
rest of the field. Heterocycle synthesis was also possible under these reaction conditions
to produce molcules 14 and 15. The scope of the electrophile overall was less successful
as seen in Figure 15. 4-bromoacetophenone was the most optimized electrophile, and
attempting to vary this lead us to Molecules 12 and 13.
Conclusion
Overall, a new reaction was developed mimicking the Haloform reaction. This
reaction differs itself from that based on its scope and reaction conditions used to achieve
a successful reaction. The Haloform reaction only found success with oxygen based
nucleophiles, while this reaction works with nitrogen and oxygen based nucleophiles.
The conditions of this reaction differ greatly as we use strong acid while the Haloform
reaction used a strong base in order to substitute ketone.
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Chapter 2B
Experimental Data for New Reaction Methodology
General Experimental Data
Unless otherwise noted, all reactions were performed in flame-dried glassware
under an atmosphere of nitrogen or argon using dried reagents and solvents. All
chemicals were purchased from commercial vendors and used without further
purification. Anhydrous clean solvents were purchased from commercial vendors.
Flash chromatography was performed using standard grade silica gel 60 230-400
mesh from SORBENT Technologies or was performed using a Biotage Flash Purification
system equipped with Biotage SNAP columns. All purifications were performed using
gradients of mixtures of ethyl acetate and hexanes. Analytical thin-layer chromatography
was carried out using Silica G TLC plates, 200 μm with UV254 fluorescent indicator
(SORBENT Technologies), and visualization was performed by staining and/or by
absorbance of UV light.
NMR spectra were recorded using a Varian Mercury Plus spectrometer (400 MHz
for 1H-NMR; 100 MHz for

13

C-NMR). Chemical shifts are reported in parts per million

(ppm) and were calibrated according to residual protonated solvent. Mass spectroscopy
data was collected using an Agilent 1100-Series LC/MSD Trap LC-MS or a Micromass
Quattromicro with a Waters 2795 Separations Module LC-MS with acetonitrile
containing 0.1% formic acid as the mobile phase in positive ionization mode. Purity was
determined on a Agilent 1100 series equipped with a Phenomenex Kinetex 2.6 µm C18UPLC column using a gradient of water to acetonitrile with 0.1% TFA.
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Procedure A: This is a two-day reaction. On day one, the electrophile 4bromoacetophenone(122.2mg, 1EQ), DriSolv acetonitrile(1.22mL, 0.5M), acetic
anhydride(0.171mL, 3EQ), and nitric acid(0.171mL, 6EQ) were added on ice to a 20ml
scintillation vial. This solution stirred overnight. On day two, Nethyldiisopropylamine(1.3mL, 12EQ) was added along with each reaction’s respective
nucleophile(0.5EQ) both on ice. This solution stirred overnight and the next day the
reaction was complete.
Procedure B: This is a three-day reaction. The first and second day of this reaction
is the same as procedure A. On day three, acetic acid(1.22mL) is added and the reaction
is stirred overnight at 60oC.
1H-NMR

and 13C-NMR Sepctra for all Final Compounds and Key Intermediates

4-bromobenzoic acid, 1.
Product was produced following Procedure A with KOH (0.5 EQ) as nucleophile and
yielded 42.9 mg, 0.213 mmol, 69.6%. 1H NMR (400 MHz, CD3OD) δ 12.0(1H) 7.91 (d,
2H), 7.64 (d, 2H). 13C NMR (101 MHz, CD3OD) δ 168.82, 132.79, 132.45, 131.12,
128.77. ESI-MS calculated for C7H6BrO2, 202.027 [M+H], observed, 202.498; HPLC
purity=90.8%.
Methyl 4-bromobenzoate, 2.
Product was produced following Procedure A with methanol (0.5EQ) as nucleophile and
yielded 53.4 mg, 0.248 mmol, 81.0%. 1H NMR (400 MHz, CDCl3) δ 7.90 (d, 2H), 7.58
(d, 2H), 3.91 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 166.60, 131.94, 131.34, 129.25,
123

128.27, 52.54. ESI-MS calculated for C8H8BrO2, 216.971 [M+H], observed, 216.414;
HPLC purity=87.5%.
Phenyl 4-bromobenzoate, 3.
Product was produced following Procedure A with phenol (0.5EQ) as nucleophile and
yielded 54.3 mg, 0.196 mmol, 64.0%. H NMR (400 MHz, CDCl3) δ 8.07 (d, 2H), 7.66 (d,
2H), 7.44 (t, 2H), 7.29 (t, 1H), 7.21 (dd, 2H). 13C NMR (101 MHz, CDCl3) δ 164.72,
150.96, 132.18, 131.88, 129.77, 129.05, 128.70, 126.28, 121.83. ESI-MS calculated for
C13H10BrO2, 278.125 [M+H], observed, 278.414; HPLC purity=90.6%.
Benzyl 4-bromobenzoate, 4.
Product was produced following Procedure A with benzyl alcohol (0.5EQ) as nucleophile
and yielded 49.8 mg, 0.171 mmol, 55.8%. 1H NMR (400 MHz, CDCl3) δ 7.94 (d, 2H),
7.58 (d, 2H), 7.47 – 7.31 (m, 5H), 5.36 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 165.84,
135.88, 132.64, 131.86, 131.36, 129.15, 128.78, 128.52, 128.39, 67.11. ESI-MS
calculated for C14H12BrO2, 292.152 [M+H], observed, 292.125; HPLC purity=96.4%.
4-bromo-N-butylbenzamide, 5.
Product was produced following Procedure A with 1-butyl amine (0.5EQ) as nucleophile
and yielded 63.4 mg, 0.258 mmol, 80.8%. 1H NMR (400 MHz, CDCl3) δ 7.62 (d, 2H),
7.55 (d, 2H), 6.15 (s, 1H), 3.44 (q, J = 7.2, 5.6 Hz, 2H), 1.66 – 1.52 (m, 2H), 1.47 – 1.33
(m, 2H), 0.95 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 166.73, 133.74, 131.89,
128.61, 126.10, 40.07, 31.80, 20.29, 13.92. ESI-MS calculated for C11H15BrNO, 257.151
[M+H], observed, 257.151; HPLC purity = 91.5%.
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N-benzyl-4-bromobenzamide, 6.
Product was produced following Procedure A with benzyl amine (0.5EQ) as nucleophile
and yielded 70.6 mg, 0.243 mmol, 79.4%. 1H NMR (400 MHz, CDCl3) δ 7.65 (d, 2H),
7.55 (d, 2H), 7.39 – 7.27 (m, 5H), 6.49 (s, 1H), 4.61 (d, J = 5.6 Hz, 2H). 13C NMR (101
MHz, CDCl3) δ 166.52, 138.01, 133.28, 131.94, 128.96, 128.72, 128.06, 127.87, 126.37,
44.36. ESI-MS calculated from C14H13BrNO, 291.168 [M+H], observed, 291.388; HPLC
purity=94.1%.
(4-bromophenyl)(piperidin-1-yl)methanone, 7.
Product was produced following Procedure A with piperidine (0.5EQ) as nucleophile and
yielded 48.7 mg, 0.182 mmol, 59.3%. 1H NMR (400 MHz, CDCl3) δ 7.53 (d, 2H), 7.26
(d, 2H), 3.68 (s, 2H), 3.32 (s, 2H), 1.80 – 1.40 (m, 6H). 13C NMR (101 MHz, CDCl3) δ
169.37, 135.40, 131.76, 128.70, 123.75, 48.89, 43.36, 26.55, 25.78, 24.65. ESI-MS
calculated from C12H15BrNO, 269.162 [M+H], observed, 269.162; HPLC purity=90.1%.
4-bromo-N-methoxy-N-methylbenzamide, 8.
Product was produced following Procedure A with N,O dimethyl hydroxylamine HCl
(0.5EQ) as nucleophile and yielded 58.1 mg, 0.238 mmol, 77.7%. 1H NMR (400 MHz,
CDCl3) δ 7.58 (d, 2H), 7.54 (d, 2H), 3.53 (s, 3H), 3.35 (s, 3H). 13C NMR (101 MHz,
CDCl3) δ 168.85, 132.89, 131.37, 130.15, 125.28, 61.27, 33.64. ESI-MS calculated from
C9H11BrNO2, 245.096 [M+H], observed, 245.096; HPLC purity=95.7%.
4-bromo-N-phenylbenzamide, 9.
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Product was produced following Procedure A with aniline (0.5EQ) as nucleophile and
yielded 34.1 mg, 0.124 mmol, 40.3%. 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.5 Hz,
3H), 7.62 (d, 4H), 7.38 (t, 2H), 7.17 (t, J = 7.5, 1.1 Hz, 1H). 13C NMR (101 MHz, CDCl3)
δ 164.86, 137.74, 133.92, 132.20, 129.31, 128.76, 126.76, 124.98, 120.38. ESI-MS
calculated from C13H11BrNO, 277.141 [M+H], observed, 277.141; HPLC purity=80.2%.
3-(4-bromobenzoyl)oxazolidin-2-one, 10.
Product was produced following Procedure A with oxazolidinone (0.5EQ) as nucleophile
and yielded 9.2 mg, 0.034 mmol, 11.1%. 1H NMR (400 MHz, CDCl3) δ 7.57 (d, 2H),
7.55 (d, 2H), 4.51 (t, 2H), 4.18 (t, 2H). 13C NMR (101 MHz, CDCl3) δ 168.98, 153.28,
131.42, 131.36, 130.86, 127.55, 62.46, 43.82. ESI-MS calculated from C10H9BrNO3,
271.090[M+H], observed, 271.090; HPLC purity=80.5%.
2-(4-bromophenyl)-1H-benzo[d]imidazole, 15.
Product was produced following Procedure B with ortho-phenyllene diamine (0.5EQ) as
nucleophile and yielded 42.0 mg, 0.154 mmol, 85.7%. 1H NMR (400 MHz, CD3OD) δ
8.00 (d, 2H), 7.72 (d, 2H), 7.65 – 7.58 (m, 2H), 7.31 – 7.25 (m, 2H). 13C NMR (101
MHz, CD3OD) δ 152.24, 133.40, 130.13, 129.45, 125.53, 124.18. ESI-Ms calculated
from C13H10BrN2, 274.141 [M+H], observed, 274.141; HPLC purity=93.8%.
N-benzylpivalamide, 13.
Product was produced following Procedure A with pN-benzyl-4-bromobenzamide
(0.5EQ) as nucleophile, pinocolone (1EQ) as electrophile, and yielded 114.7 mg, 0.600
mmol, 58.4%. 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.20 (m, 5H), 6.14 (s, 1H), 4.39 (d, J
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= 5.7 Hz, 2H), 1.21 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 178.42, 138.68, 128.65,
127.54, 127.34, 43.49, 38.70, 27.61. ESI-MS calculated from C12H18NO, 192.282
[M+H], observed, 192.380.
1-(4-bromophenyl)-2,2-dinitroethen-1-ol, 11.
Isolated intermediate. 1H NMR (400 MHz, CDCl3) δ 8.00 (d, 2H), 7.72 (d, 2H). 13C NMR
(101 MHz, CDCl3) δ 181.79, 152.56, 133.48, 132.65, 131.82, 131.37.
2-(4-bromophenyl)benzo[d]oxazole, 14.
The product was produced following Procedure B with 2-amino phenol (0.5EQ) as the
nucleophile and yielded 80.6 mg, 0.294 mmol, 95.8%. 1H NMR (400 MHz, Chloroformd) δ 7.78 (d, J = 8.6 Hz, 2H), 7.66 (d, J = 8.5 Hz, 2H), 7.25 (d, J = 8.9 Hz, 3H), 7.20 –
7.15 (m, 1H), 7.07 (dd, J = 8.1, 1.4 Hz, 1H), 6.94 (td, J = 7.9, 1.4 Hz, 1H). 13C NMR
(101 MHz, cdcl3) δ 165.99, 148.56, 132.23, 132.12, 132.08, 132.00, 128.85, 127.40,
127.36, 125.42, 122.28, 120.82, 119.71. ESI-MS calculated from C13H9BrNO, 275.125
[M+H], observed, 275.234; HPLC purity = 79.1%.
4-bromobenzoic acid, 1.

127

128

Methyl 4-bromobenzoate, 2.

129

130

Phenyl 4-bromobenzoate, 3.

131

132

Benzyl 4-bromobenzoate, 4.

133

134

4-bromo-N-butylbenzamide, 5.

135

136

N-benzyl-4-bromobenzamide, 6.

137

138

(4-bromophenyl)(piperidin-1-yl)methanone, 7.

139

140

4-bromo-N-methoxy-N-methylbenzamide, 8.

141

142

4-bromo-N-phenylbenzamide, 9.

143

144

3-(4-bromobenzoyl)oxazolidin-2-one, 10.

145

146

N-benzylpivalamide, 13.

147

148

1-(4-bromophenyl)-2,2-dinitroethen-1-ol.

149

150

2-(4-bromophenyl)benzo[d]oxazole, 14.

151

152

153

Chapter 3A
Narrow Spectrum Antibiotic Development
Introduction
Narrow spectrum antibiotics show activity against a small scope of bacteria. We
prepared a focused series of molecules and tested their antibiotic activity against both
Acinetobacter baumannii and Pseudomonas aeruginosa. The relationship of activity
against both bacteria is identical, except this series of molecules proves to be more potent
against Acinetobacter baumannii. Based on our own work and previous publications we
believe these molecules to be inhibitors of fatty acid synthesis, giving a possible
indication to the mechanism of action, but we are currently working on further figuring
out the overall mechanism of action. Interestingly, we also see some antifungal activity
from our collaborations with Dr. Mark Hickman. Our goal is to simply alter the molecule
in various ways and use information we receive from bioassays against either bacteria to
further produce a structure activity relationship.
Reaction Mechanism
The synthesis of these molecules is achieved by reacting an aldehyde or
ketone(shown as the black portion), a hydrazine(shown as the red portion), and potassium
thiocyanate(shown as the blue portion) all in dilute HCl as solvent, allowing the reaction
to be water tolerant. These reactions were performed overnight and the product was
simply separated with vacuum filtration and then recrystallized in hot methanol to
produce pure product. The reaction was a multicomponent coupling reaction and began
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with the nucleophillic attack of phenyl hydrazine’s outer most nitrogen upon the
protonated ketone or aldehyde. This intermediate would then have nitrogen’s lone pair
come down and kick of water as a good leaving group, forming an imine intermediate.
This imine intermediate proves to be a good electrophile for potassium thiocyanate to
attack the carbonyl, which is followed by a cyclization that forms our 5 membered
heterocycle product. This reaction mechanism with arrow pushing can be seen below in
Figure 17.

Figure 17. Arrow pushing mechanism of this multicomponent coupling reaction
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Structure Activity Relationship
In order to develop an SAR for this reaction, we aimed to change one portion of
this molecule at a time so we could truly see the effect each change had on the activity of
the molecule. We begin by changing the ketone portion of the molecule, testing mostly
for sterics but also add in some electronic changes. Overall we see the activity increase
when the smaller substituents are present, such as the methyl/methyl groups or the
methyl/ethyl group. The rest of these molecules have less activity than these two
substituents, especially the larger methyl/hexyl groups. This scope can be seen below in
Figure 18.
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Figure 18. Scope of the ketone or aldehyde portion of the molecule.

Moving forward as we begin to test the various positions of the hydrazine ring for
steric and electronic effects, we only make these products with the methyl/methyl and
methyl/ethyl group. Our goal here is firstly test electronic effects. We accomplish this by
moving chlorine which is slightly electron donating from para to meta to ortho. This
shows to be most potent in the para position. From here we change the electronics by
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testing para methoxy, greatly increasing the electron donating effect, and by testing para
nitro, which introduces an electron withdrawing effect. We see an activity increase in the
para methoxy substitute, which turns out to be our current lead compound. For the para
nitro molecule, we see a huge decrease in activity. This shows a drastic difference in
activity due to the changing of electronic effects at the para position of the hydrazine
ring. We also pushed our SAR further by attempting a few other hydrazine substituents,
such removing the aromaticity from the ring or substituting the ring with more than 1
molecule. This scope of the hydrazine can be seen below in Figure 19. Overall, we find
para methoxy with the methyl/methyl ketone portion to be our current lead compound.

Figure 19. Scope of the hydrazine portion of the molecule, made with the methyl/methyl
group.
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Figure 20. Scope of the hydrazine portion of the molecule, made with the methyl/ethyl
group.

Biological Data Overview
For every molecule, we ran a growth based overnight bioassay on an incubating
plate reader. This provided us with both kinetic and end point data to evaluate our
molecules with and use in optimization. We began testing molecules against
Pseudomonas aeruginosa, which provided a trend of where our SAR was heading.
Acinetobacter baumannii proved to be 16 fold more potent comparatively, but showed
the same trend. We quickly moved to testing these molecules solely against
Acinetobacter baumannii while we changed just one portion of the molecule at a time to
find the true effect for activity change.
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Figure 21. Bioassay data against Acinetobacter baumannii for Molecule 1.
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Figure 22. Bioassay data against Acinetobacter baumannii for Molecule 2.
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The trend of the ketone portion of the molecule can be extrapolated from Figures
21 and 22 and seen further in the supporting information. As the sterics of this position
are increased, the activity is decreased. Changing the electronics of this position did not
seem to help the activity either. As we moved forward and began to change the
phenylhydrazine portion of the molecule, we did so only using the methyl/methyl ketone
and methyl/ethyl ketone but knew that our best activity would be the with the
methyl/methyl group.
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Figure 23. Bioassay data against Acinetobacter baumannii for Molecule 10.
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Figure 24. Bioassay data against Acinetobacter baumannii for Molecule 13.

As we began testing the electronics and sterics of the ring on this molecule we
quickly found that the para position was the most ideal for activity. Placing chlorine at
the para position (Molecule 10) provides a slight electron donating effect to the ring. Not
only does this increase the rate of the reaction based upon our synthesis, but also
increases the activity in comparison to having no substituent on the ring. Moving chlorine
to the meta and ortho position kills any activity the compound had, so from here we
decided to change the para position. We tested sterics by changing chlorine into bromine.
This molecule had less activity but still some. We tested electronics by drastically
changing the effect of this position. When switching the chlorine to an electron
withdrawing nitro group, we saw the activity of the molecule vanish. However, changing
chlorine to a more potent electron donating group such as a methoxy group (Molecule
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13) actually increased the activity. Figure 24 shows where our current lead compound’s
MIC might lie.
Future Directions
In order to make a breakthrough with our SAR we are aiming to change the core
structure of these molecules in order to increase stability. We believe these molecules to
have short half-lives due to our observations of the biological activity decreasing over
time at certain concentrations. If we can remove heteroatoms from the core 5-member
ring or change the sulfur to an oxygen we can possibly increase the stability and allow
these molecules to function for longer against bacteria. This has proved difficult and we
are currently altering our reaction conditions in order to complete this goal.
Conclusions
A focused series of molecules were made and tested against two bacteria for an
antibiotic effect in order to develop a structure activity relationship. Our current lead
compound is Molecule 13 with a highly electron donating group in the para position of
the phenyl hydrazine ring, with small sterics in the ketone position of the molecule.
Pushing the SAR further would require more detailed changes to the core structure of
these molecules, and this is our current focus.
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Chapter 3B
Experimental Data for Narrow Spectrum Antibiotic Development
General Experimental
Unless otherwise noted, all reactions were performed in flame-dried glassware
under an atmosphere of nitrogen or argon using dried reagents and solvents. All
chemicals were purchased from commercial vendors and used without further
purification. Anhydrous clean solvents were purchased from commercial vendors.
Flash chromatography was performed using standard grade silica gel 60 230-400
mesh from SORBENT Technologies or was performed using a Biotage Flash Purification
system equipped with Biotage SNAP columns. All purifications were performed using
gradients of mixtures of ethyl acetate and hexanes. Analytical thin-layer chromatography
was carried out using Silica G TLC plates, 200 μm with UV254 fluorescent indicator
(SORBENT Technologies), and visualization was performed by staining and/or by
absorbance of UV light.
NMR spectra were recorded using a Varian Mercury Plus spectrometer (400 MHz
for 1H-NMR; 100 MHz for

13

C-NMR). Chemical shifts are reported in parts per million

(ppm) and were calibrated according to residual protonated solvent. Mass spectroscopy
data was collected using an Agilent 1100-Series LC/MSD Trap LC-MS or a Micromass
Quattromicro with a Waters 2795 Separations Module LC-MS with acetonitrile
containing 0.1% formic acid as the mobile phase in positive ionization mode. Purity was
determined on a Agilent 1100 series equipped with a Phenomenex Kinetex 2.6 µm C18UPLC column using a gradient of water to acetonitrile with 0.1% TFA.
164

1H-NMR

and 13C-NMR Sepctra for all Final Compounds and Key Intermediates

2-phenyl-1,2,4-triazaspiro[4,5]decane-3-thione, 9, This is a two-day reaction. For day
one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3 mmol), and
phenylhydrazine (0.324 g, 3 mmol) were added to a 20 mL scintillation vial. Then,
cyclohexanone (0.311 mL, 3 mmol) was added dropwise to the vial. This solution was
stirred for 16 hours at room temperature in dark conditions. For day two, the precipitate
was vacuum filtrated and washed with water four times. Then the layer was recrystallized
with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H),
7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H). 13C-NMR
(120MHz, DMSO-d6) δ 176.17, 140.42, 127.94, 124.11, 121.47, 75.95, 34.44, 24.73,
22.17.
5,5-dimethyl-2-phenyl-1,2,4-triazolidine-3-thione, 1, This is a two-day reaction. For day
one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3 mmol), and
phenylhydrazine (0.324 g, 3 mmol) were added to a 20 mL scintillation vial. Then,
acetone (0.222 mL, 3 mmol) was added dropwise to the vial. This solution was stirred for
16 hours at room temperature in dark conditions. For day two, the precipitate was
vacuum filtrated and washed with water four times. Then the layer was recrystallized
with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H),
7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H). 13C-NMR
(120MHz, DMSO-d6) δ 176.32, 140.17, 127.87, 124.05, 121.29, 74.07, 24.96.
5-ethyl-5-pentyl-2-phenyl-1,2,4-triazolidine-3-thione, 8, This is a two-day reaction. For
day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3 mmol), and
phenylhydrazine (0.324 g, 3 mmol) were added to a 20 mL scintillation vial. Then, 3165

octanone (0.469 mL, 3 mmol) was added dropwise to the vial. This solution was stirred
for 16 hours at room temperature in dark conditions. For day two, the precipitate was
vacuum filtrated and washed with water four times. Then the layer was recrystallized
with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H),
7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H). 13C-NMR
(120MHz, DMSO-d6) δ 175.93, 140.28, 128.08, 124.26, 121.49, 79.00, 48.88, 36.56,
31.75, 29.79, 22.25, 14.08, 7.92.
5-hexyl-5-methyl-2-phenyl-1,2,4-triazolidine-3-thione, 7, This is a two-day reaction. For
day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3 mmol), and
phenylhydrazine (0.324 g, 3 mmol) were added to a 20 mL scintillation vial. Then, 2octanone (0.469 mL, 3 mmol) was added dropwise to the vial. This solution was stirred
for 16 hours at room temperature in dark conditions. For day two, the precipitate was
vacuum filtrated and washed with water four times. Then, the layer was recrystallized
with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H),
7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H). 13C-NMR
(120MHz, DMSO-d6) δ 175.96, 140.17, 127.82, 123.90, 121.14, 76.19, 31.18, 28.96,
23.21, 23.01, 22.01, 13.93.
5-ethyl-5-methyl-2-phenyl-1,2,4-triazolidine-3-thione, 2, This is a two-day reaction. For
day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3 mmol), and
phenylhydrazine (0.324 g, 3 mmol) were added to a 20 mL scintillation vial. Then, 2butanone (0.269 mL, 3 mmol) was added dropwise to the vial. This solution was stirred
for 16 hours at room temperature in dark conditions. For day two, the precipitate was
vacuum filtrated and washed with water four times. Then the layer was recrystallized
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with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H),
7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H). 13C-NMR
(120MHz, DMSO-d6) δ 175.99, 140.16, 127.91, 124.01, 121.23, 76.55, 31.76, 22.53,
7.99.
5,5-diethyl-2-phenyl-1,2,4-triazolidine-3-thione, 3, This is a two-day reaction. For day
one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3 mmol), and
phenylhydrazine (0.324 g, 3 mmol) were added to a 20 mL scintillation vial. Then, 3pentanone (0.312 mL, 3 mmol) was added dropwise to the vial. This solution was stirred
for 16 hours at room temperature in dark conditions. For day two, the precipitate was
vacuum filtrated and washed with water four times. Then the layer was recrystallized
with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H),
7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H). 13C-NMR
(120MHz, DMSO-d6) δ 175.72, 140.11, 127.84, 123.88, 121.14, 78.98, 29.09, 7.66.
5-ethyl-2-phenyl-1,2,4-triazolidine-3-thione, 5, This is a two-day reaction. For day one,
hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3 mmol), and
phenylhydrazine (0.324 g, 3 mmol) were added to a 20 mL scintillation vial. Then,
propionaldehyde (0.215 mL, 3 mmol) was added dropwise to the vial. This solution was
stirred for 16 hours at room temperature in dark conditions. For day two, the precipitate
was vacuum filtrated and washed with water four times. Then the layer was recrystallized
with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H),
7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H). 13C-NMR
(120MHz, DMSO-d6) δ 177.49, 151.53, 129.00, 122.56, 115.81, 83.45, 28.81, 7.95.
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2-phenyl-1,2,4-triazaspiro[4,4]nonane-3-thione, 6, This is a two-day reaction. For day
one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3 mmol), and
phenylhydrazine (0.324 g, 3 mmol) were added to a 20 mL scintillation vial. Then,
cyclopentanone (0.266 mL, 3 mmol) was added dropwise to the vial. This solution was
stirred for 16 hours at room temperature in dark conditions. For day two, the precipitate
was vacuum filtrated and washed with water four times. Then the layer was recrystallized
with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H),
7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H). 13C-NMR
(120MHz, DMSO-d6) δ 176.35, 140.04, 127.90, 124.08, 121.31, 83.87, 35.80, 22.92.
5-(hydroxymethyl)-5-methyl-2-phenyl-1,2,4-triazolidine-3-thione, 4, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and phenylhydrazine (0.296 g, 3 mmol) were added to a 20 mL scintillation vial.
Then, hydroxyacetone (0.206 mL, 3 mmol) was added dropwise to the vial. This solution
was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ 176.27, 140.19, 127.88, 124.16, 121.58, 64.47, 20.30.

13

2-(4-chlorophenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 10, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 4-chlorophenylhydrazine (0.537 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, acetone (0.222 mL, 3 mmol) was added to the vial. This solution
was stirred for 16 hours at room temperature in dark conditions. For day two, the
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precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ 176.29, 139.13, 127.80, 127.71, 122.45, 74.19, 24.96.

13

2-(4-bromophenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 15, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 4-bromophenylhydrazine (0.671 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, acetone (0.222 mL, 3 mmol) was added to the vial. This solution
was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ 176.25, 139.57, 130.70, 122.74, 115.81, 74.17, 24.94.

13

2-(2-chlorophenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 12, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 2-chlorophenylhydrazine (0.537 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, acetone (0.222 mL, 3 mmol) was added to the vial. This solution
was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ 178.50, 132.57, 130.89, 129.86, 129.51, 127.42,

13

109.54, 75.67, 25.05.
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2-(4-methoxyphenyl)-5,5-dimethyl-1,2,4-triazoline-3-thione, 13, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 4-methoxyphenylhydrazine (0.524 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, acetone (0.222 mL, 3 mmol) was added to the vial. This solution
was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ 176.31, 156.24, 133.15, 123.90, 113.10, 74.07, 55.27,

13

24.98.
2-(4-cyclohexylphenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 16, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and cyclohexylhydrazine (0.452 g, 3 mmol) were added to a 20 mL scintillation
vial. Then, acetone (0.222 mL, 3 mmol) was added to the vial. This solution was stirred
for 16 hours at room temperature in dark conditions. For day two, the precipitate was
vacuum filtrated and washed with water four times. Then the layer was recrystallized
with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H),
7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H). 13C-NMR
(120MHz, DMSO-d6) δ 176.73, 74.67, 54.02, 29.49, 25.01.
2-(4-chlorophenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 17, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 4-chlorophenylhydrazine (0.537 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, 2-butanone (0.269 mL, 3 mmol) was added to the vial. This
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solution was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ 175.96, 139.11, 127.80, 127.59, 122.32, 76.63, 31.75,

13

22.49, 7.94.
2-(4-bromophenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 22, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 4-bromophenylhydrazine (0.671 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, 2-butanone (0.269 mL, 3 mmol) was added to the vial. This
solution was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ 175.93, 139.54, 130.69, 122.61, 115.68, 76.62, 31.75,

13

22.48, 7.93.
2-(2-chlorophenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 19, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 2-chlorophenylhydrazine (0.537 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, 2-butanone (0.269 mL, 3 mmol) was added to the vial. This
solution was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
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8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ δ 153.39, 152.31, 138.09, 126.30, 124.38, 111.62,

13

77.20, 31.95, 16.27, 11.15.
5-ethyl-2-(4-methoxyphenyl)-5-methyl-1,2,4-triazolidine-3-thione, 20, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 4-methoxyphenylhydrazine (0.524 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, 2-butanone (0.269 mL, 3 mmol) was added to the vial. This
solution was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ 175.89, 156.15, 133.14, 123.72, 113.08, 76.50, 55.26,

13

31.68, 22.52, 7.96.
5-ethyl-5-methyl-2-(4-nitrophenyl)-1,2,4-triazolidine-3-thione, 23, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 4-nitrophenylhydrazine (0.569 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, 2-butanone (0.269 mL, 3 mmol) was added to the vial. This
solution was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ 13C NMR (101 MHz, DMSO-d6) δ 176.19, 152.96,

13

151.88, 125.87, 111.19, 76.77, 31.52, 15.84, 10.72.
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2-(2,4-dinitrophenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 24, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 2,4-dinitrophenylhydrazine (0.594 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, 2-butanone (0.269 mL, 3 mmol) was added to the vial. This
solution was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J =
8.6 Hz, 2H), 7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H).
C-NMR (120MHz, DMSO-d6) δ 161.21, 145.06, 136.93, 130.40, 123.35, 116.27,

13

109.83, 48.87, 31.90, 16.06, 10.61.
2-(4-cyclohexylphenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 25, This is a twoday reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g,
3 mmol), and cyclohexylhydrazine (0.452 g, 3 mmol) were added to a 20 mL scintillation
vial. Then, 2-butanone (0.269 mL, 3 mmol) was added to the vial. This solution was
stirred for 16 hours at room temperature in dark conditions. For day two, the precipitate
was vacuum filtrated and washed with water four times. Then the layer was recrystallized
with methanol. 1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.95 (d, J = 8.6 Hz, 2H),
7.33 (t, J = 7.7 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 6.73 (s, 1H), 1.34 (s, 6H). 13C-NMR
(120MHz, DMSO-d6) δ 176.40, 77.32, 54.34, 31.25, 29.61, 25.15, 22.33, 8.20.
2-(3-chlorophenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 11, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 3-chlorophenylhydrazine (0.537 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, acetone (0.222 mL, 3 mmol) was added to the vial. This solution
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was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 8.17 (s, 1H), 7.98 (d, J =
8.3 Hz, 1H), 7.36 (t, J = 8.1 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 1.34 (s, 6H). 13C NMR
(101 MHz, DMSO-d6) δ 176.27, 141.56, 132.19, 129.60, 123.30, 119.82, 118.81, 74.14,
24.89.
2-(3-chlorophenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 18, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 3-chlorophenylhydrazie (0.537 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, 2-butanone (0.269 mL, 3 mmol) was added to the vial. This
solution was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 8.22 – 8.16 (m, 1H), 8.04
– 7.97 (m, 1H), 7.39 – 7.31 (m, 1H), 7.18 – 7.09 (m, 1H), 1.58 (d, J = 7.4 Hz, 2H), 1.33
(s, 3H), 0.88 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 175.97, 141.52,
132.19, 129.59, 123.18, 119.68, 118.69, 76.59, 31.68, 22.44, 7.88.
2-(3-methoxyphenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 14, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 3-methoxyphenylhydrazine (0.524 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, acetone (0.222 mL, 3 mmol) was added to the vial. This solution
was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 7.51 (d, J = 8.1 Hz, 1H),
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7.23 (t, J = 8.2 Hz, 1H), 6.69 (d, J = 13.3 Hz, 2H), 3.74 (s, 3H), 1.33 (s, 6H). 13C NMR
(101 MHz, DMSO-d6) δ 176.26, 158.75, 141.32, 128.67, 113.25, 109.38, 106.91, 73.97,
55.12, 24.92.
5-ethyl-2-(3-methoxyphenyl)-5-methyl-1,2,4-triazolidine-3-thione, 21, This is a two-day
reaction. For day one, hydrochloric acid (3 mL, 1 M), potassium thiocyanate (0.291g, 3
mmol), and 3-methoxyphenylhydrazie (0.524 g, 3 mmol) were added to a 20 mL
scintillation vial. Then, 2-butanone (0.269 mL, 3 mmol) was added to the vial. This
solution was stirred for 16 hours at room temperature in dark conditions. For day two, the
precipitate was vacuum filtrated and washed with water four times. Then the layer was
recrystallized with methanol. 1H NMR (400 MHz, DMSO-d6) δ 7.74 (s, 1H), 7.53 (d, J =
8.1 Hz, 1H), 7.22 (t, J = 8.1 Hz, 1H), 6.68 (d, J = 8.2 Hz, 1H), 3.73 (s, 3H), 1.57 (d, J =
7.4 Hz, 2H), 1.32 (s, 3H), 0.89 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ
175.93, 158.74, 141.29, 128.67, 113.13, 109.22, 106.84, 76.41, 31.69, 55.10, 22.43, 7.91.

2-phenyl-1,2,4-triazaspiro[4,5]decane-3-thione, 9.

175

176

5,5-dimethyl-2-phenyl-1,2,4-triazolidine-3-thione, 1.

177

178

5-ethyl-5-pentyl-2-phenyl-1,2,4-triazolidine-3-thione, 8.

179

180

5-hexyl-5-methyl-2-phenyl-1,2,4-triazolidine-3-thione, 7.

181

182

5-ethyl-5-methyl-2-phenyl-1,2,4-triazolidine-3-thione, 2.

183

184

5,5-diethyl-2-phenyl-1,2,4-triazolidine-3-thione, 3.

185

186

5-ethyl-2-phenyl-1,2,4-triazolidine-3-thione, 5.

187

188

2-phenyl-1,2,4-triazaspiro[4,4]nonane-3-thione, 6.

189

190

5-(hydroxymethyl)-5-methyl-2-phenyl-1,2,4-triazolidine-3-thione, 4.

191

192

2-(4-chlorophenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 10.

193

194

2-(4-bromophenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 15.

195

196

2-(2-chlorophenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 12.

197

198

2-(4-methoxyphenyl)-5,5-dimethyl-1,2,4-triazoline-3-thione, 13.

199

200

2-(4-cyclohexylphenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 16.

201

202

2-(4-chlorophenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 17.

203

204

2-(4-bromophenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 22.

205

206

2-(2-chlorophenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 19.

207

208

5-ethyl-2-(4-methoxyphenyl)-5-methyl-1,2,4-triazolidine-3-thione, 20.

209

210

5-ethyl-5-methyl-2-(4-nitrophenyl)-1,2,4-triazolidine-3-thione, 23.

211

212

2-(2,4-dinitrophenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 24.

213

214

2-(4-cyclohexylphenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 25.

215

216

2-(3-chlorophenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 11.

217

218

2-(3-chlorophenyl)-5-ethyl-5-methyl-1,2,4-triazolidine-3-thione, 18.

219

220

2-(3-methoxyphenyl)-5,5-dimethyl-1,2,4-triazolidine-3-thione, 14.

221

222

5-ethyl-2-(3-methoxyphenyl)-5-methyl-1,2,4-triazolidine-3-thione, 21.

223

224

Bioassay Procedure
Overnight cultures of Pseudomonas aeruginosa or Staphylococcus aureus were
prepared by inoculating 5mL of LB broth from freezer stocks stored at -80° C that
consisted of 40% glycerol. The cultures were prepared in sterile 14mL culture tubes and
placed in a shaking incubator at 30° C and 120 rpm’s for 24 hrs with the lids in the open
position. Following overnight incubation, each culture was diluted 40:1 in LB broth and
vortexed. The diluted overnight cultures were then dispensed into clear bottom 96-well
microplates at a volume of 150μL per well. The first row then received an additional
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30μL of the diluted overnight culture, and 20μL of 20mg/mL of each compound
dissolved in DMSO. This step yielded a final volume of 200μL with a 2mg/mL
concentration of each compound throughout the first row of the plate in order to prepare
for a serial dilution. A 4:1 serial dilution was then performed using a 12-channel
micropipette by removing 50μL of the first row and dispensing into the 150μL of diluted
overnight culture in the row below. The wells were then thoroughly mixed and this step
was repeated from rows A through G. 50μL of the culture were then removed from row G
following the dilution in order to maintain a consistent volume of 150μL per well. Row H
of the 96 well plate was used for a control and a blank. Wells H1 through H6 were
subject to the same 4:1 serial dilution as mentioned above using 20μL of DMSO without
any compound. Wells H7 through H12 were used as blanks containing only 150μL of the
diluted overnight culture. 50μL of mineral oil were then dispensed into each of the 96
wells to yield a final volume of 200μL and to prevent evaporation of the LB broth during
the following 24 hour incubation. The 96 well plate was then placed into a Molecular
Devices Spectramax i3x multimode microplate reader. The plate reader was set to 37°C
and recorded the absorption of each well at 420 nm at 15 minute intervals for 24 hours.
The plate was subject to shaking at 120 rpm for 15 minutes in between each absorption
reading. The values obtained were used to generate growth curves of each well to
investigate antimicrobial activity of each comound and analyzed using Prism Graphpad
software. Samples were run in duplicate by using two rows on the same plate for each
compound and averaging the absorption values.
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